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Abstract Influences of adenosine 2A receptor (A2AR) activity
on the cardiac transcriptome and genesis of endotoxemic myocarditis are unclear. We applied transcriptomic profiling (39 K
Affymetrix arrays) to identify A2AR-sensitive molecules, revealed by receptor knockout (KO), in healthy and endotoxemic
hearts. Baseline cardiac function was unaltered and only 37
A2AR-sensitive genes modified by A2AR KO (≥1.2-fold change,
<5 % FDR); the five most induced are Mtr, Ppbp, Chac1, Ctsk
and Cnpy2 and the five most repressed are Hp, Yipf4, Acta1,
Cidec and Map3k2. Few canonical paths were impacted, with
altered Gnb1, Prkar2b, Pde3b and Map3k2 (among others)
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implicating modified G protein/cAMP/PKA and cGMP/NOS
signalling. Lipopolysaccharide (LPS; 20 mg/kg) challenge for
24 h modified >4100 transcripts in wild-type (WT) myocardium
(≥1.5-fold change, FDR < 1 %); the most induced are Lcn2
(+590); Saa3 (+516); Serpina3n (+122); Cxcl9 (+101) and
Cxcl1 (+89) and the most repressed are Car3 (−38); Adipoq
(−17); Atgrl1/Aplnr (−14); H19 (−11) and Itga8 (−8).
Canonical responses centred on inflammation, immunity, cell
death and remodelling, with pronounced amplification of tolllike receptor (TLR) and underlying JAK-STAT, NFκB and
MAPK pathways, and a ‘cardio-depressant’ profile
encompassing suppressed ß-adrenergic, PKA and Ca2+ signalling, electromechanical and mitochondrial function (and major
shifts in transcripts impacting function/injury including Lcn2,
S100a8/S100a9, Icam1/Vcam and Nox2 induction, and Adipoq,
Igf1 and Aplnr repression). Endotoxemic responses were selectively modified by A2AR KO, supporting inflammatory suppression via A2AR sensitive shifts in regulators of NFκB and JAKSTAT signalling (IκBζ, IκBα, STAT1, CDKN1a and RRAS2)
without impacting the cardio-depressant gene profile. Data indicate A2ARs exert minor effects in un-stressed myocardium and
selectively suppress NFκB and JAK-STATsignalling and cardiac
injury without influencing cardiac depression in endotoxemia.
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Uncontrolled inflammation with sepsis and the systemic inflammatory response syndrome induce multiple organ dysfunction,
including cardiac abnormalities key to disease progression and
mortality [1]. Unravelling the complex mechanisms governing
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myocardial injury [1, 2] is not only fundamentally important but
also reveals targets for manipulating outcomes. In this regard,
adenosine 2A receptors (A2ARs) may fulfil a broadly suppressive
role to limit inflammatory injury in multiple tissues [3–6] and
enhance myocardial resistance to ischaemic/hypoxic insult, presenting a potentially useful therapeutic target [3, 7]. In heart, this
G protein-coupled receptor (GPCR) influences coronary tone
and angiogenesis, cardiac contractility, fibroblast growth and fibrosis and may mediate protection via ischaemic pre- and postconditioning [8–10]. Inflammatory modulation contributes to
this latter cardioprotection [9–11], together with the regulation
of myocyte kinase signals to limit oxidative stress, mitochondrial
dysfunction and cell death [12–14]. However, impacts of the
A2AR on integrated myocardial responses to uncontrolled inflammation, and the mechanisms underlying such effects, remain
to be elucidated.
While adenosine analogues and A2AR agonists can limit
endotoxemic or septic injury in lung [15, 16], liver [17], brain
[18] and heart [19–21], the roles of intrinsic A2AR activity are
less clear. Receptor deletion fails to modify inflammatory
markers/injury in some studies [22], reportedly worsens
endotoxemic injury in heart [23] and lung [15, 24] and improves survival in models of polymicrobial sepsis [25, 26].
These divergent outcomes may reflect different cell- and
organ-specific effects of A2ARs, for example promoting
inflammasome formation and macrophage-dependent injury
[27], impairing bacterial clearance [25], while activating cardiac survival signalling and suppressing inflammation [3, 7,
12–14]. Nonetheless, opposing effects of endogenous vs. exogenous (or amplified endogenous) adenosine are evident
within cell types, for example inhibiting vs. promoting vascular myocyte NOS activation with inflammation [28]. The
chronicity of receptor activation may also be critical to
tissue-specific responses; while acute or transient increases
in adenosine levels/receptor activity are generally beneficial
(improving tissue perfusion, ischemic/hypoxic tolerance and
reducing cytokines/inflammation), chronic elevations may be
detrimental, exaggerating fibrotic processes via A2BRs in lung
[29] or A2A and A2BRs in liver [30, 31], for example. Whether
acute vs. chronic A2AR activity induces opposing myocardial
outcomes is unknown, though prolonged A2B agonism limits
rather than promotes fibrosis in injured myocardium [32], as
does prolonged A1 agonism [33].
Additional to questions regarding protective vs. deleterious
effects of the A2AR, the evolution of myocardial inflammatory
injury and ‘endotoxemic myocarditis’ itself is complex and
incompletely defined [1, 2]. Effects in non-cardiac tissues involve TLR/CD14-dependent NFκB and MAPK signalling
and interferon/cytokine engagement of the JAK-STAT path
[34–36]. These mechanisms likely participate in heart, with
evidence NFκB and IκB kinase promotes cardiac dysfunction
in sepsis/endotoxemia [37, 38], while JAK-STAT signalling
mediates dysfunction and cell death in myocardial ischemia
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[39, 40]. In vivo observations suggest marked expansion of
this signalling in intact myocardium [41, 42], contrasting
in vitro evidence that cardiomyocyte NFκB and IκB kinase
signalling is only transiently LPS responsive [43].
Importantly, these paths are inhibited by A2ARs in other cells,
with exogenous agonism decreasing [44, 45] and A2AR KO
increasing NFκB activity [6]. Nonetheless, these paths can
also promote myocardial stress-resistance and survival under
conditions that include inflammatory cytokine challenge
[46–48]. The molecular underpinnings of endotoxemic myocarditis in vivo warrant further investigation, as do the mechanisms countering this dysfunction (including A2AR activity).
We thus undertook broad-scale transcriptomic profiling of
hearts from WT and A2AR KO mice, at baseline and following
endotoxin challenge: shifts in gene expression can shed light
on both functions of the A2AR, and pathogenesis and modulation of endotoxemic myocarditis. There are no prior analyses of transcriptome-wide effects of A2AR activity in myocardium, and relatively few of the in situ cardiac response to
endotoxemia or sepsis [41, 42, 49].

Materials and methods
Animals
All animal procedures conformed to the Guide for the Care
and Use of Laboratory Animals published by the NIH (publication number 85-25, revised 1996). This project (and protocols for care of animals) was approved by the Animal Care
and Use Committees of St. Jude Children’s Research Hospital
and the University of Tennessee Health Sciences Center. The
A2AR KO mice and WT littermates were obtained from a subcolony of the original lines generated and characterized by
Ledent et al. [50]. Analysis of cardiac tissue confirms ablation
of A2AR transcript without compensatory shifts in other adenosine receptors (Fig. S1). Mice were bred and maintained onsite at St. Jude Children’s Research Hospital, with standard
laboratory food and water available ad libitum. Animal genotype was confirmed by PCR analysis of tail snips. All animals
were originated from the same breeding series and were
matched for age and weight. Male and female mice were used
with equal representation in each experimental group. Both
A2AR KO and WT littermate mice were randomly allocated
to receive either an intraperitoneal injection of 20 mg/kg LPS
isolated from E. coli (Sigma-Aldrich, St. Louis, MO) or an
equal volume of sterile saline vehicle. Blood was sampled at
12 and 24 h of LPS challenge to assess shifts in blood cell
counts and circulating cytokines/biomarkers, as detailed by us
previously [23]. Mice were monitored for the development of
symptoms of illness or distress (lethargy, piloerection,
hunched posture and/or respiratory distress) during the initial
12 h post-injection and every 4 h thereafter; observation of
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any combination of symptoms prompted immediate euthanasia. All efforts were made to minimize animal suffering and
distress. No analgesic or anaesthetic was administered other
than for euthanasia immediately on evidence of illness/
distress.
We initially tested responses to 24 h LPS challenge in both
young (14 week) and old (46–52 weeks) WT and A2AR KO
mice. However, absent overt symptoms of illness/distress,
there was nonetheless significant mortality in aged LPStreated mice, as detailed in the “Results” section and in
Supplementary material. Cause of death in older animals
was not determined. As a result of mortality, detailed molecular interrogation of cardiac gene expression (n = 6–8 per
group), together with analyses of cardiac function in isolated
hearts (n = 8–9 per group) and haematological/biomarker assessment (n = 6–9 per group) is necessarily constrained to the
young group of mice.
Langendorff perfusion and tissue sampling
After 24 h of LPS challenge, mice were anaesthetised with
sodium pentobarbital (50 mg/kg intraperitoneally), a thoracotomy performed and hearts excised into ice-cold KrebsHenseleit solution for Langendorff perfusion, as detailed previously [23], or sampling of ventricular tissue for RNA preparation. Briefly, for perfusions, the aorta was immediately
cannulated and hearts perfused at 80 mmHg with modified
Krebs-Henseleit solution containing (in mM): NaCl, 120;
NaHCO3, 25; KCl, 4.7; CaCl2, 2.5; MgCl2, 1.2; KH2PO4,
1.2; D-glucose, 15 and EDTA, 0.5. Perfusion fluid was maintained at 37 °C and bubbled with a mix of 95 % O2/5 %
CO2 at 37 °C to provide a pH of 7.4. Ventricular function
was monitored via a fluid-filled plastic film balloon in the left
ventricle, connected to a P23 XL pressure transducer (ViggoSpectramed, Oxnard, CA, USA). Coronary flow was monitored via a flow-probe in the aortic perfusion line, connected
to a T206 flowmeter (Transonic Systems Inc., Ithaca, NY,
USA). Functional data were recorded at 1 KHz on MacLab
data acquisition system (ADInstruments, Castle Hill,
Australia). Statistical comparisons of cardiovascular
(Table 1) and blood parameters (Figs. 1 and 2) between groups
were made via analysis of variance (ANOVA), with a
Newman-Keuls post hoc test for specific comparisons. A
P < 0.05 was considered indicative of significance in all tests.
RNA preparation and microarray hybridisation
Ventricular tissue was isolated, frozen in liquid N2 and stored
at −80 °C until analysis. Tissue was subsequently homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA) and total
RNA isolated according to manufacturer’s protocol. The RNA
was further treated with 50 U of DNase I (Promega, Madison,
WI) for 15 min at 37 °C and purified on RNeasy spin columns
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(Qiagen, Hilden, Germany). Total RNA yield and integrity
were determined spectrophotometrically and via capillary
electrophoresis on a 2100 BioAnalyzer (Agilent, Palo Alto,
CA), respectively.
Microarray experiments were performed at the St. Jude
Hartwell Center Core Facility according to manufacturers’
protocols. Briefly, first- and second-strand complementary
DNA (cDNA) synthesis reactions were performed using the
SuperScript Choice System (Invitrogen, Carlsbad, CA)
followed by in vitro transcription using biotin-labelled
dNTPs (ENZO Diagnostics, Farmingdale, NY).
Complementary RNA (cRNA) samples were fragmented
and individually hybridized to GeneChip® Mouse Genome
430 2.0 microarrays (Affymetrix, Santa Clara, CA). Each microarray quantified expression of over 39,000 transcripts, including full-length mRNA sequences and expressed sequence
tags (ESTs). Following hybridization, microarrays were
washed and stained with streptavidin–phycoerythrin
(Molecular Probes, Eugene, OR) before scanning. Image files
were converted into probe-set data (*.CEL files) via
Affymetrix MAS 5.0 software. Experimental data are accessible through GEO Series accession number GSE44363 at
http://www.ncbi.nlm.nih.gov/geo.
Microarray data and statistical analyses
Raw expression data were background corrected, normalized and log2 transformed using the Robust Multichip
Average (RMA) method in BioConductor/R [51]. Data
were filtered to include only transcripts detected on ≥3
arrays, with 25,646 transcripts passing this quality criterion (i.e. consistently detected in cardiac tissue). Log2 ratio
values were generated by subtracting median expression
values for WT vehicle-treated animals from each sample
per probe before importing into TIGR MeV 4.0 software
for statistical analysis [52]. The Significant Analysis of
Microarrays (SAM) algorithm was used to correct for
multiple comparisons and non-parametrically select differentially expressed genes using a median false discovery
rate (FDR) ≤1.0 % [53]. In addition, a two-factor analysis
of variance (ANOVA) was performed. To generate a data
sets similar in size and false-positive rates, a P value
<0.005 was employed. The lists of differentially
expressed genes generated via SAM or ANOVA were then
compared to identify 8110 shared transcripts for further
investigation and validation (Fig. S2). This output was
subjected to appropriate pair-wise SAM comparisons, incorporating a 1.5-fold change cut-off [54]. Significant
transcripts were annotated using Ingenuity Pathway
Analysis (IPA) (v8.7; Ingenuity® Systems, Redwood
City, CA, USA), providing insight into biological/
molecular themes over-represented in response to A2AR
deletion and/or LPS. In brief, for each pathway/process,
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Table 1 Ex vivo cardiovascular
function in perfused for hearts
from WT and A2AR KO mice
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Functional parameter

WT (n = 8)

A2AR KO
(n = 8)

WT + LPS
(n = 9)

A2AR
KO + LPS(n = 9)

Coronary flow (ml/min/g)

16.7 ± 0.7

15.6 ± 1.2

16.9 ± 1.7

15.9 ± 0.6

Heart rate (beats/min)
Systolic pressure (mmHg)

341 ± 7
113 ± 6

341 ± 7
118 ± 5

352 ± 9
80 ± 7*

353 ± 9
86 ± 3*

6039 ± 247

6039 ± 163

4310 ± 422*

4489 ± 220*

−3664 ± 129
0.15 ± 0.01

−3718 ± 132
0.13 ± 0.02

2666 ± 197*
0.21 ± 0.02*

−2846 ± 105*
0.18 ± 0.02*

+dP/dt (mmHg/s)
−dP/dt (mmHg/s)
Coronary ‘Supply:Demand’ (ml/
min/g/mmHg)

All data are means ± S.E.M. Functional parameters were measured after 30 min of normothermic aerobic
perfusion. Intrinsic heart rate is recorded immediately prior to pacing. *P < 0.05 vs. corresponding values in
Vehicle-treated hearts. Coronary ‘Supply:Demand’ was calculated as the ratio of coronary flow rate (O2 supply)
relative to ventricular systolic pressure (reflecting myocardial O2 demand). dP/dt, first derivative of pressure over
time. *P < 0.05 vs. untreated. A2AR KO did not independently modify functional parameters

the fraction of differentially expressed genes was compared with the fraction of total genes in that path (shown
in tables as the ‘Ratio’, useful for determining which
pathways/processes overlap the most with altered genes

in specific datasets). The probability of involvement of
the respective number of modified transcripts in a
path/process is expressed as a P value or range (values
<0.05 considered significant).
Validation of expression changes and Adora expression via
RT-qPCR

Fig. 1 Effects of A2AR KO and LPS (24 h) on markers of cardiac
damage (TnI) and systemic inflammation (CRP) and the acute phase
response (haptoglobin). Data represent means ± S.E.M. *P < 0.05 vs.
vehicle; †P < 0.05 vs. wild-type

Two-step RT-qPCR, utilizing SYBR Green I, was
employed to confirm differential gene expression for 11
transcripts (primer details provided in Table S1), as previously described [54]. Six additional genes (Actb,
Gapdh, Hprt1, Pgk1, Ppia and Ubc) were assessed using
GeNorm to determine utility as reference genes [55].
Following GeNorm assessment, Actb was found to be
most stable (M = 0.03) and served as the endogenous
reference control for all messenger RNAs (mRNAs)
assessed via RT-qPCR. Briefly, 1 μg total RNA was used
to synthesize cDNA using the Superscript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. RT-qPCR was performed in a CFX96 Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). Final reaction volumes
(10 μL) included 5 μL iQ SYBR-Green Supermix (BioRad, Hercules, CA), 100 nM of each primer and 4 μL of a
1:20 dilution of cDNA. Optimal qPCR cycling conditions
entailed an initial denaturation at 95 °C for 3 min followed by 40 cycles of 95 °C for 15 s/62 °C for 60 s. After the
final PCR cycle, reactions underwent melt curve analysis
to detect non-specific amplicons. All reactions were performed in triplicate, with each plate containing an equal
number of samples from each group, a calibrator control
derived from a pool of all cDNA samples and a notemplate control. PCR amplification efficiencies (90–
110 %) for each primer pair were calculated using a 5log serial dilution of calibrator sample. PCR data were
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Fig. 2 Effects of A2AR KO and LPS (24 h) on haematological parameters and cytokines. Data represent means ± S.E.M. *P < 0.05 vs. vehicle; †P < 0.05
vs. wild-type

Results

not modify cardiac or coronary function in healthy or
endotoxemic hearts (Table 1). Cardiovascular, blood cell
and cytokine responses to LPS in WT and A2AR KO
mice have been reported by us previously [23]. Similar
outcomes were apparent here for markers of inflammation and injury (Fig. 1), haematological parameters and
cytokines (Fig. 2) and cardiac function (Table 1). Data
confirm significant inflammatory activation, cellular injury and cardiac dysfunction with LPS, with A2AR deletion amplifying changes in IL-5 and markers of cardiac injury (TnI) and systemic inflammatory stress (haptoglobin, CRP), without altering myocardial dysfunction
or circulating levels of IL-4, IL-10, IFNγ or TNFα.

Impact of A2AAR deletion on cardiovascular function
and inflammatory markers

Impact of A2AAR deletion on survival

Deletion of the A2AR was confirmed in cardiac tissue,
with no compensatory changes in transcription of the
other three sub-types (Fig. S1). Receptor deletion did

Interestingly, we acquire preliminary evidence LPSdependent mortality is age- and sex-dependent and selectively
exaggerated by A2AR KO in older males (Fig. S3). Initially,

analysed using CFX Manager v1.6 (Bio-Rad, Hercules,
CA). Baseline subtractions and threshold settings above
background were applied to all data. The calibrator sample was used to normalize inter-assay variations, with the
threshold coefficient of variance for intra- and inter-assay
replicates <1 % and <5 %, respectively. Normalized expression (ΔΔCq) was calculated, with mRNAs normalized to Actb levels and the calibrator control then log2transformed.
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testing responses to LPS challenge in young (14 week) and
middle-aged (46–52 week) mice—since age may exaggerate
impacts of endotoxemia [56]—we recorded 20 % mortality in
older WT mice with A2AR KO specifically reducing survival
to <20 % in older males (Fig. S3). No mortality was recorded
in young mice challenged with LPS (or any vehicle-treated
groups). There is thus a trend to greater mortality with age,
with a major survival effect of A2AR activity in older males.
While molecular interrogations here are thus limited to young
mice (in which LPS was non-lethal), it is possible A2AR activity may be increasingly crucial to survival in older, stressintolerant males (whereas younger animals and females may
possess intrinsically greater resistance to injury/death [57]).
This is discussed further in the online Supplementary material.
Cardiac transcriptomic response to A2AR KO
Few transcriptional differences were detected between WT
and A2AR KO hearts, with the amplitude of changes modest
(up to threefold). Employing an initial 1.5-fold cut-off and 1 %
FDR identified only 13 genes (Table 2). To enhance the power
of subsequent pathway analysis, these criteria were relaxed to
1.2-fold and 5 %, encompassing 37 altered transcripts
(Table 2). There was a little impact of A2AR deletion on inflammatory mediators, with modest induction of a CXC chemokine (Ppbp, +2.1), a regulator of cell migration/adhesion
and cytokinesis (Iqgap1, +1.6) and a hemopoietic cytokine
(Tslp, +1.6), together with repression of Hp (−2.7) and an Ig
adhesion molecule regulating T-lymphocyte development
(Mpzl2, −1.7) (Table 2).
Analysis via the IPA suite identified 112 canonical pathways sensitive to A2AR activity in healthy hearts (Table S2),
the most highly modified shown in Table 3. The top five
included relaxin signalling, cardiac β-adrenergic signalling,
cellular effects of sildenafil, PKA signalling and photo-transduction. The influence of A2AR KO on these and other paths
can be attributed to repression of Prkar2b (−1.8), Gnb1 (−1.7)
and Pde3b (−1.7), collectively impacting G protein-coupled
cAMP/PKA dependent signalling (encompassing relaxin, αand β-adrenergic, NO, Ca2+ and hypertrophic signalling).
Additionally, Map3k2 (−2) and Nfat2c (+1.3) span many paths
modified by A2AR KO. Modulation of these five transcripts
contributes to 48 of the top 50 A2AR-sensitive canonical pathways. Overall, A2AR deletion exerts an inhibitory effect on G
protein-coupled, cAMP/PKA, and MEKK2 signalling downstream of this and other GPCRs.
Multiple biological functions appear sensitive to A2AR KO
(see Table S3), the most significant (Table 4) revolving around
cellular development, growth, movement and death, together
with humoral immunity and haematological development and
intercellular signalling. Toxicological functions included high
representation of liver processes (fibrosis, damage, steatosis,
hepatitis and inflammation) together with six cardiac
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functions (Table 4). The latter included cardiac arteriopathy
(Ank3, Pon1, Cux2, Gk5, Pde3b, Dgat1 and Nsmce1), infarction (Pon1 and Acta1) and transcripts involved in failure and
hypertrophy (Pde3b and Nfat2c).
Cardiac transcriptomic response to LPS
Analysis via the SAM algorithm (1.5-fold threshold, 1 %
FDR) identified 4146 transcripts modified after 24 h of LPS
challenge (see Table S4 for full details). Figure 3 presents the
25 most induced and repressed transcripts, with responses in
A2AR KO hearts shown for comparison. Many of the most
highly modified are predictably involved in inflammation/
innate immunity, together with tissue development/remodelling. The most LPS-responsive cytokines/chemokines are
shown in Fig. 4, with responses in KO hearts highlighted.
Functional classifications, using a twofold threshold to narrow the focus to the most highly modified paths, identify 236
canonical pathways (Table S5), with the most significantly
modified presented in Table 5. Data confirm a profound inflammatory and immune response, with marked upregulation
of TLR/MyD88 and interferon signalling (Fig. 5), the acute
phase response (Fig. S4), IRF activation (Fig. S5) and PRRand RIG-1-like signalling (Figs. S6 and S7). These changes
primarily reflect shifts in underpinning NFκB, JAK-STAT,
MAPK and PI3K/Akt signalling (Figs. S8–S12).
Additionally, LPS upregulated cell death signalling
(Figs. S13 and S14) and modified paths involved in cellular
differentiation, movement, growth and remodelling (e.g.
Figs. S15 and S17). The top LPS-sensitive biological functions are summarized in Table S6, with biologic and cardiovascular toxicological responses fully detailed in Table S7 and
S8 in the Supplementary material.
Unsurprisingly, many highly responsive transcripts were
involved in inflammation (Figs. 3 and 4, Table 5): within the
most induced are interferon-related genes (Ifit1, Ifit2, Ifit3,
Igtp1, Igtp2, Igtp3, Iigp1, Iigp2, Ifi44 and Irf7) and
inflammatory/immune modulators (Lcn2, Saa3, Socs3,
S100a8, S100a9, Mpa2l, Cxcl1, Cxcl9, Cxcl10, IL6, Ptx3,
Serpina3n, Csf3 and Mt2). Several are potentially injurious
to the heart: the most highly induced transcript encodes
lipocalin-2, which regulates inflammation and matrix degradation, is implicated in heart failure [58] and promotes cardiac
apoptosis [59]; CXCL1 is a potent neutrophil chemoattractant;
CXCL9 stimulates cytokine production and T-cell
proliferation/recruitment; CXCL10 mediates CXCR3+ cell
migration and augments inflammation. Conversely, some
transcripts encode anti-inflammatory and potentially protective molecules: SERPINA3N (α1-antichymotrypsin) inhibits
proteases involved in inflammation; the pentraxin PTX3 is
expressed in heart with inflammation and limits cell death;
SOCS3 is a negative feedback regulator of IL-6 signalling,
implicated in sex-dependent cardiac stress-resistance;
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Genes modified by A2AR KO in healthy myocardium

Gene

Gene name

Affymetrix ID

Fold-Change

%FDR

UpRegulated
Mtr

5-methyltetrahydrofolate-homocysteine methyltransferase

1439811_at

2.83

0.00

Ppbp
Chac1

pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)
ChaC, cation transport regulator homologue 1 (E. coli)

1418480_at
1451382_at

2.08
1.85

3.93
0.00

Ctsk
Cnpy2

cathepsin K
canopy 2 homologue (zebrafish)

1450652_at
1416507_at

1.84
1.67

0.00
0.00

Iqgap1

IQ motif containing GTPase activating protein 1

1445724_at

1.64

3.85

Tslp
Nav3

thymic stromal lymphopoietin
neuron navigator 3

1450004_at
1456144_at

1.63
1.61

3.93
0.00

Cux2
Slc38a1

cut-like homeobox 2
solute carrier family 38, member 1

1447500_at
1454764_s_at

1.60
1.47

0.00
0.00

Nsmce1

non-SMC element 1 homologue (S. cerevisiae)

1436121_a_at

1.42

0.00

Gk5
Rpl22

glycerol kinase 5 (putative)
ribosomal protein L22

1436210_at
1448398_s_at

1.38
1.37

3.93
0.00

C11orf75
Slco5a1

chromosome 11 open reading frame 75
solute carrier organic anion transporter family, member 5 A1

1419403_at
1440874_at

1.37
1.31

0.00
4.21

Nfatc2

nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2

1426032_at

1.28

4.70

Dgat1
Ticam1
Mrap

Downregulated
diacylglycerol O-acyltransferase homologue 1 (mouse)
toll-like receptor adaptor molecule 1
melanocortin 2 receptor accessory protein

1418295_s_at
1454676_s_at
1451371_at

−1.24
−1.24
−1.31

2.39
3.05
3.05

Ppa1
Ell2
Fmod
Ptger3
Pkdcc

pyrophosphatase (inorganic) 1
elongation factor, RNA polymerase II, 2
fibromodulin
prostaglandin E receptor 3 (subtype EP3)
protein kinase domain containing, cytoplasmic homologue (mouse)

1416939_at
1450744_at
1456084_x_at
1450344_a_at
1454838_s_at

−1.32
−1.33
−1.47
−1.49
−1.50

4.31
2.53
4.31
2.68
4.61

Ank3
Sacs
Pon1
Gnb1
Mpzl2

ankyrin 3, node of Ranvier (ankyrin G)
spastic ataxia of Charlevoix-Saguenay (sacsin)
paraoxonase 1
guanine nucleotide binding protein (G protein), beta polypeptide 1
myelin protein zero-like 2

1457288_at
1434958_at
1418190_at
1425908_at
1416236_a_at

−1.58
−1.61
−1.68
−1.72
−1.74

3.05
2.39
0.00
4.54
0.00

Pde3b
Prkar2b
Slc16a9
Map3k2
Cidec

phosphodiesterase 3B, cGMP-inhibited
protein kinase, cAMP-dependent, regulatory, type II, beta

1433694_at
1438664_at

−1.74
−1.78

solute carrier family 16, member 9 (monocarboxylic acid transporter 9)
mitogen-activated protein kinase kinase kinase 2 (MEKK2)
cell death-inducing DFFA-like effector c

1429726_at
1438719_at
1452260_at

−1.84
−2.01
−2.08

0.00
3.05
0.00
0.00
0.00

Acta1
Yipf4
Hp

actin, alpha 1, skeletal muscle
Yip1 domain family, member 4
haptoglobin

1427735_a_at
1426417_at
1448881_at

−2.14
−2.51
−2.70

2.68
4.54
0.00

Data shown for transcripts for which myocardial expression levels were modified by A2AR KO by a factor of ≥1.2-fold (FDR <5 %)

metallothionein-2, induced by STAT3-related signalling, mediates cardioprotection and can limit dysfunction in sepsis.
Cardio-depressant molecular profile Major pathways critical to contractile function were substantially impacted,
identifying a ‘cardio-depressed’ molecular profile in
hearts of endotoxemic mice (Figs. S18–S21). β-

Adrenergic signalling was broadly suppressed
(Fig. S18), including reduced transcripts for β1-adrenergic
receptor, G protein, adenylate cyclase, PKA and related
signalling elements (Ppp1r14c, Gng11, Prkar2b, Pde7a,
Ppp1r3c, Ppp1r14a, Pkia and Adcy7), together with induction of Pde4b (AMP-dependent phosphodiesterase).
The PKA pathway itself was substantially suppressed
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(Fig. S19), including reductions in PKA RIα (Prkar1a),
PKA RIIα (Prkar2a), PKA RIIβ (Prkar2b), PKAα
(Prkaca) and PKA-Cβ (Prkacb), while PKA RIβ
(Prkar1b) was modestly induced (+1.5). Transcripts for
Gαs and Gαq also declined.
Cellular Ca2+ signalling paths were repressed (Fig. S20),
with reductions in key elements including: Camk1d, Ryr3,
Casq1, Mef2c, Casq2, Calm1, Hdac9, Myh7b, Tpm2,
Myh11, Rcan1, Myl7, Atp2b2, Prkar2b, Tpm3 and Asph.
Mitochondrial dysfunction (Fig. S21) is also evidenced by
repression of complex I/NADH dehydrogenase components
(including Ndufv2 and 3; Ndufs4, 5, 6, 7 and 8; Ndufa3, 4, 5, 6
and 8; Ndufab1, Ndufaf1, Ndufb2, 3, 4, 7, 9, 10 and 11),
together with Complex II components (including Sdhc,
Sdhd, Uqcrb, Uqcrc1 and Uqcrfs1). Uncoupling proteins
Ucp2 and Ucp3 were also induced, while Ucp1 was repressed.
Transcript for the major activator of mitochondrial biogenesis
(Ppargc1a) was repressed.
Adenosine-related transcripts There were limited impacts on
the adenosinergic system itself, with two- to threefold upregulation of adenosine deaminase, 1.5-fold repression of adenosine
kinase, 1.7-fold induction of S-adenosylhomocysteine hydrolase and twofold induction of the ecto-nucleotidase CD39.
These changes may modify patterns of cellular adenosine generation vs. uptake and metabolism, potentially altering receptor
activation in endotoxemic tissue. A small 1.3-fold rise in
Adora2b expression was also detected.
Impact of A2AR KO on transcriptomic responses
to endotoxemia
Interestingly, A2AR activity does not broadly suppress the
effects of endotoxemia on myocardial gene expression, with
90 % of transcriptomic responses unaltered by receptor KO.
For example, Fig. 3 presents response profiles for the 25 most
induced or repressed transcripts in WT hearts, with most
shown to be insensitive to A2AR KO. Deletion selectively
enhanced induction of Lcn2, Igtp, Cxcl5, S100a8, Iigp2,
Cxcl2 and Iigp1 and repression of C1qtnf9, Colec11 and
Inmt, while reducing induction of Ifit3 and repression of
Adipoq, Gpr22, and Scube2, Ifit3 (Fig. 3). These effects support A2AR modulation of inflammatory and interferon-related
signalling responses. Nonetheless, the pattern of LPSdependent cytokine/chemokine change was largely insensitive
to A2AR KO, with specific enhancement of Cxcl5, Cxcl2, Il6
and Csf3 induction (Fig. 4). Figure 6 summarizes the select
effects of A2AR activity (revealed via KO) on TLR- and
interferon-triggered NFκB and JAK-STAT signalling responses to LPS (generally repressing these pathways).
To gain further insight into these specific effects of A2AR
KO, we identified those LPS-responsive transcripts whose
expression changes were increased or reduced ≥1.5-fold by
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A2AR KO (Table S9). Effects of LPS on 282 genes were
augmented ≥1.5-fold following A2AR KO, with a further 9
responsive to LPS specifically in KO and not WT hearts
(Table S9). The most highly augmented included 25 transcripts increased ≥twofold by KO. Many A2AR-sensitive transcripts are associated with pro-inflammatory signalling (e.g.
Igtp, Lcn2, Cxcl5, S100a8, Iigp2, Cxcl2, Il6, Ifi202b, Hp and
Cxcl9), with data supporting inhibitory effects of the A2AR on
the responsiveness of canonical pathways that include the
acute phase response, glucocorticoid receptor, Erk/MAPK,
HIF1α and JAK-STAT signalling (Table 6).
Deletion of the A2AR reduced or entirely eliminated 134
gene responses to LPS (Table S9). Responses entirely A2ARdependent included repression of Sacs, Cidec, Gnb1l,
Mtap1b, Msi2, Cdh2, Lpgat1, Tbx3, Slc38a1, Sdc1, Reln,
Ext1 and Pvrl3, and induction of Rit1, Ezh1, Eif4ebp1 and
Abhd4 (Table S9). The transcripts most sensitive to A2AR
KO included Dnmt3a, Qk, Sema5a, Srpk2, Car3, Ucp1,
Rsad2 and Dnajb14. Highly LPS-responsive changes
counteracted by A2AR KO included: Ifit3, Rsad2, Cxcl13,
Ms4a6d, Oasl1, Ms4a4c, Sema5a, Tyki and Hmox1. Intrinsic
A2AR activity thus also promotes LPS-dependent shifts in
select genes associated with immune/inflammatory processes,
including orphan nuclear receptor and PPARα activation,
PRR responses to infection, AMPK signalling and NFκB signalling (Table 6).
In terms of biological functions, A2AR activity reduced
LPS responsiveness of paths related to cellular movement,
growth, signalling and death, immune cell trafficking and
haematological and cardiovascular development (Tables 7
and S10). Conversely, A2AR activity appears to augment
responses in pathways related to metabolism and transport, together with organ, haematological, cardiovascular
and lymphoid development (Table 7), with complete details of pathway responses modified by A2AR KO included in Table S10. Deletion of the A2AR also influenced
multiple toxicological functions; of 35 responses countered by A2AR KO, 12 were cardiac-specific categories
(Table S11), with reduced Adipoq and Hmox1 responses
involved in ~half. Of 46 toxicological function responses
enhanced by A2AR KO, a third was cardiac categories.
Enhanced responses for Serpine1, Kckn3 and Ppargc1a
are involved in a majority of these and are also implicated
in cardiac dysfunction.
Importantly, a relatively small set of A2AR responsive
genes are implicated in a majority of these A2AR sensitive
biological pathways and processes and can be considered
A2AR-dependent ‘nodes’ or points of regulatory convergence. Of the top 50 pathway responses augmented by
A 2A R KO, Pi3kr1 is implicated in 42; Rras2 in 40;
Stat1, Vegfc, Pgf and Pak6 each in 12; Atf4 in 11;
Cdkn1a in 9 and Rhoj and IL6 each in 8 (Tables 6 and
S10). Of the leading 50 canonical responses inhibited by
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Top 20 canonical pathways modified by A2AAR KO in healthy myocardium

Canonical pathways

P value

Ratio

Genes

Relaxin signalling

3.55E-03

1.99E-02

Gnb1, Prkar2b, Pde3b

Cardiac β-adrenergic signalling

3.55E-03

2.11E-02

Gnb1, Prkar2b, Pde3b

Cellular effects of sildenafil (Viagra)
Protein Kinase A signalling

3.98E-03
6.03E-03

1.99E-02
1.26E-02

Acta1, Prkar2b, Pde3b
Gnb1, Prkar2b, Pde3b, Nfatc2

Phototransduction pathway
Germ cell-sertoli cell junction signalling

6.03E-03
6.31E-03

3.08E-02
1.88E-02

Gnb1, Prkar2b
Iqgap1, Acta1, Map3k2

Calcium signalling

8.71E-03

1.47E-02

Prkar2b, Nfatc2, Acta1

Glutamate receptor signalling
Caveolar-mediated endocytosis signalling

9.55E-03
1.41E-02

2.86E-02
2.35E-02

Gnb1, Slc38a1
Acta1, Map3K2

Nitric oxide signalling in the cardiovascular system
Leptin signalling in obesity

1.48E-02
1.55E-02

2.02E-02
2.38E-02

Prkar2b, Pde3b
Prkar2b, Pde3b

Cardiac hypertrophy signalling

1.78E-02

1.22E-02

Gnb1, Prkar2b, Map3k2

TR/RXR Activation
SAPK/JNK signalling

2.09E-02
2.14E-02

2.02E-02
1.98E-02

Hp, Pde3b
Gnb1, Map3k2

Colorectal cancer metastasis signalling
α-Adrenergic signalling

2.14E-02
2.19E-02

1.17E-02
1.89E-02

Gnb1, Prkar2b, Ptger3
Gnb1, Prkar2b

RANK signalling in osteoclasts

2.19E-02

2.04E-02

Nfatc2, Map3K2

G Beta Gamma signalling
IL-1 signalling
fMLP signalling in neutrophils

2.24E-02
2.29E-02
2.95E-02

1.68E-02
1.89E-02
1.57E-02

Gnb1, Prkar2b
Gnb1, Prkar2b
Gnb1, Nfatc2

Canonical signalling paths modified by A2AR KO are shown, ranked according to P values determined by a Fisher’s Exact Test. Also shown is a ratio
value reflecting the number of molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in
the pathway

A 2A R KO, Rac2 was implicated in 34, Nfkbie in 21,
Prkar2b in 10, Hmox1 and Eif2ak2 each in 6 and
Eif4ebp1 and Cyp2b6 each in 5 (Tables 6 and S10).
These data point to an influence of intrinsic A2AR activity
on key signalling responses, including G protein, PKA,
S TAT 1 a n d N F κ B - d e p e n d e n t p r o c e s s e s ( s e e
Supplementary material for additional discussion). While
the absence of A2ARs impacted inflammatory and underlying signalling changes in endotoxemia, paths implicated
in endotoxemic cardio-depression (ß-adrenergic and PKA
signalling, Ca2+ handling, excitation-contraction coupling
and mitochondrial function; Figs. S18–S21) were not
among those sensitive to A2AR KO (Table 6), consistent
with a lack of effect of A2AR KO on contractile dysfunction itself (Table 1).

PCR analysis of select transcripts
Quantitative RT-PCR analysis supports microarraydetermined changes in transcripts selected for differential responsiveness to LPS and A 2A R KO (Fig. 7).
While expression ratios vary slightly between the two
methods, a significant linear relationship was apparent

between both measures (with a slope > 1 suggesting
greater dynamic range for RT-qPCR measurement).

Discussion
The present study characterizes impacts of A2AR deletion on the myocardial transcriptome, markers of inflammation and cardiac function and injury in healthy and
endotoxemic mice. Data indicate A2AR activity exerts
limited effects in un-stressed myocardium, with
transcriptomic changes limited to G protein,
cAMP/PKA and cGMP/NO signalling downstream of
this and other GPCRs (Tables 2 and 3). However, during endotoxemia, absence of A2ARs exaggerated myocardial injury (and age- and sex-dependent mortality),
without substantially modifying patterns of cytokine release, myocardial cytokine/chemokine transcription or
contractile depression. The latter is consistent with insensitivity of the ‘cardio-depressant’ profile in
endotoxemic hearts to A2AR KO. Rather, data reveal
A2AR activity selectively influences transcription of regulators of NFκB and JAK-STAT signalling during
endotoxemia, which may limit myocardial inflammation
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and injury. Additional changes with A2AR KO suggest
potential influences on insulin-resistance, hypertrophy/
remodelling and vascular control/angiogenesis in
endotoxemia.
A2AR activity and the transcriptome in un-stressed
myocardium
Modest impacts of A 2A R KO in un-stressed hearts
(Table 2) are consistent with a largely retaliatory or
stress-responsive role for myocardial A2ARs. Indeed, deletion failed to modify cardiac or vascular function, and
circulating CRP, haptoglobin and cytokines in healthy animals. Functional annotation of transcripts supports A2ARdependent shifts in relaxin, adrenergic, Ca 2+ , PKA,
SAPK/JNK and hypertrophic pathways (Tables 3 and
S2), involved in cellular growth/movement/death, immune
and cell-to-cell signalling, and toxicological processes of
fibrosis, cell damage and inflammation. This profile stems
from a handful of changes spanning pathways (i.e. Gnb1,
Nfat2c, Acta1, Prkar2b, Map3k2 and Pde3b), supporting
effects of A2AR activity on G protein and cAMP/PKA
signalling downstream of the receptor [5, 8, 60].
Deletion of the A2AR has been shown to reduce cAMP
and PKA activation in other cell types [61], consistent
with impacts of KO here (Table 3). The altered MEKK2
path is also linked to G protein/Rac-dependent signalling
distal to this and other GPCRs. In terms of vasoregulatory
functions of the A2AR, shifts in inter-related pathways
involved in relaxin signalling, cellular effects of sildenafil
and NO signalling (Table 3) support modulation of
cGMP/NOS dependent control, while cardiac arteriopathy
was identified as a pathologic process sensitive to A2AR
KO (Table 4). These rather limited transcriptomic changes
in healthy myocardium are consistent with observations in
other tissues. For example, Yu et al. [62] found A2AR KO
alters a very small sub-set of transcripts in healthy striatum (implicating A2AR sensitive EGR-2 control), with
expression changes also modest (a majority ≤twofold).
Others report no impact of A2AR KO on myocardial expression of RAC1, ERK1/2, p38-MAPK or JNK [14],
though phospho-activation of the latter kinases was impaired, potentially reflecting shifts in cAMP/PKA and
MEKK2 signalling.
Transcriptomic profile of endotoxemic myocardium
Myocardial injury and dysfunction are critical determinants of circulatory changes and mortality with uncontrolled inflammation; however, their mechanistic basis is
poorly defined. Transcriptomic interrogation can reveal
elements of these complex responses, though there are
few analyses of myocardial [41, 42, 49] or
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cardiomyocyte [43, 49] responses to endotoxin/sepsis.
Approximately 15 % of the 25,646 transcripts expressed
in murine hearts were modified in endotoxemia
(Table S4), encompassing a multiplicity of canonical
paths and functions (Tables 5, S5–S7). Many are consistent with those highlighted by Wong et al. in more
limited analysis of endotoxemic rats [41] and Rudiger
et al. in a rat faecal peritonitis model [49]. The myocardial response involves profound upregulation of
immune/inflammatory paths (Figs. 3–5 and S4–S7), the
most highly modified including acute-phase response,
PRR/TLR and interferon/IRF signalling (Table 5).
Underlying NFκB, JAK-STAT and MAPK/PI3K paths
are up-regulated (Tables 5, S5 and S7; Figs. S8–S12),
with NFκB/JAK-STAT mechanistically linking the top
five canonical pathway responses. Integrated signalling
via NFκB and JAK-STAT paths thus appears central to
myocardial endotoxemia, as in other tissues. In other
tissues, these paths are also targeted by A2ARs to suppress inflammatory/immune responses [44, 45, 58], with
KO augmenting NFκB activation in macrophages, for
example [6].
Amplified cardiac TLR and interferon signalling Since
uncontrolled inflammation induces cellular injury/death,
pro-inflammatory TLR/CD14 signalling is the subject to
negative control. However, this path was transcriptionally amplified in endotoxemic myocardium (Fig. 5), including receptor molecules (Cd14, Tlr1, Tlr2, Tlr3 and
Tlr4) and LPS-binding protein (Lbp), transduction molecules (Cr3/Mac1 and Cr4), MyD88, TIRAP and
MyD88 targets (Il6 and Il1b), MyD88-independent signal components (Tbk1, Cxcl10, Ccl2 and Ccl5) and
d o w n s t r e a m J A K - S TAT s i g n a l l i n g ( F i g . S 9 ) .
Upregulated TLR and MyD88-dependent and independent signalling are consistent with changes in rat sepsis
[49], though Tlr4, Cd14 and Tirap induction here was
not apparent in the rat model. Sweeney et al. [63] recently reported a novel MyD88-independent path linking
TLR2/TLR4 signalling to Ppargc1a, encoding the mitochondrial biogenesis co-regulator PGC-1α. However,
despite induction of elements of this path here (including Tlr2, Tlr3, Tlr4 and Irf7), cardiac Ppargc1a was
repressed by LPS, a response potentially exaggerating
mitochondrial dysfunction and countered by A 2A R
activity.
Interferon signalling transducing inflammatory/TLR
responses was also upregulated (Fig. 5), including a
majority of gene targets and the path of IRF activation
by PRRs (Figs. S5–S7). This entailed induction of
membrane (Tlr2, Tlr3 and Tlr4), cytosolic (Ddx58,
Ifih1, Eif2ak2 and Oas1) and extracellular (C1q, C3,
C3a and Ptx3) receptors, and downstream mediators
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Top 20 biological and toxicological functions modified by A2AAR KO in healthy myocardium

Biological pathway
Cellular development

P values

7.34E-04–4.5E02
Cellular growth and proliferation
7.34E-04–4.01E02
Haematological system development and
7.34E-04–4.5Efunction
02
Humoral immune response
7.34E-04–4.5E02
Cell-to-cell signalling and interaction
1.53E-03–4.74E02
Amino acid metabolism
2.55E-03–5.09E03
Carbohydrate metabolism
2.55E-03–4.72E02
Cell death
2.55E-03–4.5E02
Cell morphology
2.55E-03–3.68E02
Cellular assembly and organization
2.55E-03–4.01E02
Cellular compromise
2.55E-03–4.01E02
Cellular function and maintenance
2.55E-03–1.52E02
Cellular movement
2.55E-03–4.58E02
Connective tissue development and function 2.55E-03–3.02E02
Connective tissue disorders
2.55E-03–5.09E03
Developmental disorder
2.55E-03–2.55E03
Genetic disorder
2.55E-03–4.01E02
Hair and skin development and function
2.55E-03–5.09E03
Immune cell trafficking
2.55E-03–3.51E02
Inflammatory response
2.55E-03–4.67E02
Molecular toxicological function
P values
Liver fibrosis
3.01E-03
Liver damage
1.43E-02
Liver steatosis
2.45E-02
Cardiac arteriopathy
3.41E-02
Cardiac infarction
3.76E-02
Liver hepatitis
4.41E-02
Hepatocellular carcinoma
4.43E-02
Liver steatohepatitis
5.67E-02
Renal proliferation
7.90E-02
Liver inflammation
9.36E-02
Pulmonary hypertension
1.08E-01
Nephrosis
1.10E-01
Cardiac congestive cardiac failure
1.63E-01
Heart failure
1.63E-01
Renal nephritis
2.50E-01

Genes
Mrap, Ctsk, Sacs, Prkar2b, Ptger3, Nfatc2, Tslp, Map3k2
Mrap, Ppbp, Nfatc2, Tslp
Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Tslp, Map3k2
Nfatc2, Fmod, Tslp
Ank3, Ptger3, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp, Map3k2
Slc38a1
Gnb1, Pon1, Ppbp, Ppa1
Ppbp, Nfatc2, Tslp, Map3k2
Ank3, Ptger3, Nfatc2, Cnpy2, Iqgap1, Tslp
Ank3, Ctsk, Nfatc2, Fmod, Cnpy2, Iqgap1, Acta1
Ank3, Hp, Ctsk, Ptger3, Ppbp
Hp, Ppbp, Nfatc2, Tslp, Map3k2
Gnb1, Ctsk, Hp, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp
Ctsk, Rpl22, Ptger3, Pde3b, Ppbp, Cidec, Nfatc2
Nfatc2
Ctsk
Ank3, Ctsk, Ptger3, Cidec, Iqgap1, Tslp, Mrap, Gnb1, Pon1, Hp, Prkar2b, Pde3b, Nfatc2,
Dgat1, Acta1
Ptger3, Dgat1
Hp, Ticam1, Ppbp, Nfatc2, Tslp
Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Fmod, Tslp
Genes
Hp, Tslp
Ticam1, Tslp
Pde3b
Ank3, Cux2, Dgat1, Gk5, Nsmce1, Pde3b, Pon1
Acta1, Pon1
Pde3b
Hp, Iqgap1
Pde3b
Tslp
Hp
Ptger3
Pde3b
Pde3b
Pde3b
Pde3b

Enriched biological/toxicological functions of A2AR KO sensitive transcripts are listed according to P values or ranges determined by a Fisher’s Exact
Test

(Il6, Irf7 and Rantes). These shifts in TLR/CD14,
MyD88-dependent and -independent and interferon/IRF

signalling are relevant to temporal expansion of molecular changes [41, 42] and injury progression in
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Fig. 3 The 25 most induced and 25 most repressed transcripts in hearts
from young (2–3 month) mice challenged with LPS for 24 h. Mice were
injected with 20 mg/kg LPS or saline vehicle and left ventricular tissue
isolated for analysis 24 h later. Data from both wild-type and A2AR KO
hearts are shown for comparison (n = 6–8/group). Data are means ±
S.E.M

endotoxemia: CD14 [64] and TLR4 [65, 66] both mediate cardiac dysfunction and injury and MyD88 signalling promotes cardiac hypertrophy [67], inflammation
and injury [68, 69]. These profound responses diverge
from in vitro data suggesting dampened/transient impacts of LPS on isolated myocyte NFκB and IκB kinase
[43, 63].
Endotoxemic cardio-depression Cardiomyocyte and myocardial function is LPS-sensitive and depressed in
endotoxemia [21, 23, 70, 71] (Table 1). This has been linked
to abnormalities in myofibrillar Ca2+ sensitivity [70, 71], adrenergic control [71–74] and mitochondrial function [75], together with cell death [23, 76, 77]. Transient changes in preload may also mediate early reversible depression in vivo [78].
Transcriptomic data reveal a cardio-depressant profile
entailing suppression of key determinants of contraction, including Ca2+, β-adrenergic and PKA signalling, mitochondrial function and electromechanical coupling (Figs. S18–S21).
Importantly, and despite other impacts, A2AR expression did
not influence this cardio-depressant profile nor modify contractile depression (Table 1) [23].
Suppression of β-adrenergic and Ca2+ signalling is
consistent with desensitization in hearts and myocytes
[71–73], and transcriptional changes in a rat model of
faecal peritonitis [49]. Despite overlap with the latter
response, the β1- rather than β2-adrenoceptor is depressed in endotoxemic mouse heart (Fig. S18), while
reductions in AKAP, PP1, PP2A, NCX and L-type Ca2+
channel components observed here were not evident in
the peritonitis model. Nonetheless, data collectively implicate β-adrenergic dysfunction as a common
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Fig. 4 Effects of A2AR KO on the most LPS-responsive cytokines in
wild-type hearts. Mice were injected with 20 mg/kg LPS or saline vehicle,
and left ventricular tissue isolated for analysis 24 h later. Data from both
wild-type and A2AR KO hearts are shown for comparison (n = 6–8/
group). Data are means ± S.E.M

component of cardio-depression, consistent with reductions observed in β-adrenoceptor expression [73], tissue
noradrenaline and adrenaline [73] and adrenoceptor
stimulation of cAMP and Ca2+ fluxes [73]. In terms of
approaches to inotropic support, coincident depression
of adrenoceptor, PKA and Ca2+ signalling may limit
the value of interventions targeting these effectors.
Abnormalities within the contractile apparatus itself (repressed α-tropomyosin, troponin-T, α-actin and titin
transcription) may also be relevant. Targeting mitochondrial dysfunction may more broadly improve cardiac
outcomes: repression of Complex I components
(Fig. S21) is consistent with Complex I specific dysfunction and ROS generation in mitochondria from
endotoxemic hearts [75, 79].
Additional cardio-depressant changes include altered
TLR4 and fibroblast factor signalling, suppression of
substrate metabolism and IGF-1 signalling (Fig. S22)
and induction of inhibitory S100a8/S100a9, Icam1,
Vcam1, Cybb (NOX2), Ptgs2 (COX2) and the TNF-α
receptors Tnfr1 and Fas. Marked induction of S100 A8
and S100 A9 (TLR4 activators promoting endotoxemic
injury) has been observed in LPS-treated myocytes, involving MyD88 and NFκB signalling [80]. Intriguingly,
two adipokines with opposing actions, relevant to cardiac dysfunction, were among the most responsive to
LPS. Pro-inflammatory and injurious lipocalin-2 (Lcn2)
was the most induced (~600-fold), consistent with
changes in rodent and human myocarditis [59], while
anti-inflammatory and cardioprotective adiponectin
(Adipoq) was the second most repressed. Lipocalin-2 is
induced via IκBζ (+13 with LPS) and with heart failure,
ischemia and inflammation [81, 82]. Profound induction
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Top 20 canonical pathways modified by LPS (≥2-fold change, <1 % FDR) in WT hearts

Canonical pathways

P
value

Acute phase response signalling

9.12E- 2.02E- Socs3, Rac2, Hamp, Serping1, Nfkbie, Socs2, Cp, Saa2, Serpina3, Jak2, Il6, Rbp1,
09
01
Nr3C1, C1r, Hmox1, Shc1, Nfkbia, Cfb, Lbp, Serpine1, Nfkbib, Saa1, C3, Tnfrsf1a,
Myd88, C1s, Rac1, Serpinf1, Cebpb, Stat3, Nfkb2, Hp, Rras2, Il1Rn, C4a, C2

Interferon signalling

1.82E- 4.33E- Ifit3, Oas1, Ptpn2, Mx1, Ifi35, Irf9, Psmb8, Jak2, Tap1, Irf1, Ifitm1, Stat2, Stat1
08
01
1.38E- 2.33E- Dhx58, Nfkbie, Zbp1, Irf9, Tbk1, Il6, Nfkb2, Adar, Isg15, Ifih1, Irf7, Nfkbia, Ddx58,
07
01
Stat2, Nfkbib, Stat1, Ifit2
7.94E- 2.01E- Icam1, Lepr, Myh7b (Includes Eg:668,940), Myh11, Ccl5, Il6, Fas, Pgf, Vegfa, Il1r2,
07
01
Cxcl3, Igf1, Cyp2e1, Timp1, Lbp, Stat1, Timp2, Egfr, Il4r, Vcam1, Tnfrsf1a, Vegfc,
Igfbp5, Nfkb2, Myl7, Csf1, Cd14

Activation of IRF by cytosolic pattern
recognition receptors
Hepatic fibrosis/hepatic stellate cell
activation
Dendritic cell maturation

Role of macrophages, fibroblasts and
endothelial cells in rheumatoid arthritis

Retinoic acid mediated apoptosis signalling
Antigen presentation pathway
Role of pattern recognition receptors in
recognition of bacteria and viruses
Death receptor signalling
IL-10 signalling
Role of RIG1-like receptors in antiviral
innate immunity
IL-6 signalling
IL-8 signalling

Bladder cancer signalling
Pathogenesis of multiple sclerosis
Role of PKR in interferon induction and
antiviral response
JAK/Stat signalling
Complement system
Glucocorticoid receptor signalling

Ratio

Genes

9.12E- 1.51E- B2m, Rac2, Icam1, Lepr, Nfkbie, Pik3r5, Cd83, Il6, Jak2, Fcgr2b, Fcgr1a, Nfkbia, Hla07
01
b, Tlr3, Stat1, Nfkbib, Fcgr3a, Hla-c, Myd88, Tnfrsf1a, Relb, Rac1, Nfkb2, Tlr2,
Il1rn, Fcer1g, Stat2, Irf8
2.57E- 1.34E- Socs3, Rac2, Icam1, Mmp3, Nfkbie, Pik3r5, Jak2, Ccl5, Il6, Il17ra, Fcgr1a, Pgf, Myc,
06
01
C1r, Il1r2, Vegfa, Nfkbia, Traf3Ip2, Wif1, Cfb, Plcb1, Tlr3, Nfkbib, Prkd1, Fcgr3a,
Calm1, Adamts4, Sele, Vcam1, Myd88, Tnfrsf1a, C1s, Daam1, Rac1, Vegfc, Stat3,
Cebpb, Irak3, Tlr2, Hp, Rras2, Il1Rn, Csf1, Cxcl12, Cebpd, Sost, Wnt5a, Irak2
5.37E06
6.61E06
8.32E06
1.29E05
3.24E05
6.61E05
1.00E04
1.02E04

1.94E01
2.56E01
2.12E01
2.34E01
2.14E01
1.96E01
1.94E01
1.45E01

Parp10, Art1, Tnfsf10, Parp3, Parp12, Parp9, Tiparp, Irf1, Parp4, Bid, Parp11, Cflar,
Parp14
B2m, Psmb9, Hla-e, Hla-b, Psmb8, Hla-g, Tap1, Tap2, Tapbp, Hla-c
Ptx3, Oas1, C3, Oas2, Myd88, Pik3R5, Il6, Nfkb2, Ccl5, Tlr2, Ifih1, Clec7a, Irf7, Syk,
Ddx58, Eif2ak2, Tlr3
Hspb3, Tnfrsf1a, Nfkbie, Tnfsf10, Tbk1, Nfkb2, Fas, Daxx, Nfkbia, Bid, Cflar, Nfkbib,
Birc3, Birc2, Hspb1
Ccr1, Socs3, Il4r, Nfkbie, Il6, Stat3, Nfkb2, Fcgr2b, Il1r2, Hmox1, Nfkbia, Il1rn, Cd14,
Lbp, Nfkbib
Dhx58, Ifih1, Irf7, Nfkbia, Nfkbie, Ddx58, Tbk1, Nfkb2, Nfkbib, Trim25

Hspb3, Tnfrsf1a, Nfkbie, Il6, Nfkb2, Stat3, Cebpb, Jak2, Il1r2, Shc1, Nfkbia, Rras2,
Il1rn, Cd14, Lbp, Nfkbib, Tnfaip6, Hspb1
Rac2, Icam1, Cxcl1, Pik3r5, Pgf, Eif4ebp1, Vegfa, Hmox1, Gng11, Gna13, Nfkbib,
Prkd1, Egfr, Vcam1, Rhoc, Rac1, Vegfc, Irak3, Cstb, Myl7, Myl9 (Includes
Eg:98,932), Bcl2l1, Itgb2, Rras2, Ccnd2, Itgam, Irak2
1.26E- 1.89E- Fgf16, Mmp3, Fgf9, Mmp14, Mmp15, Vegfc, Pgf, Myc, Vegfa, Rras2, Mmp8, Fgf12,
04
01
Cdkn1a, Chd1 (Includes Eg:1105), Rps6Ka5, Fgf7, Egfr
1.45E- 5.56E- Cxcl10, Ccr1, Cxcl9, Ccl5, Cxcl11
04
01
1.58E- 2.39E- Nfkbia, Tnfrsf1a, Nfkbie, Bid, Nfkb2, Eif2ak2, Tlr3, Stat1, Nfkbib, Fcgr1a, Irf1
04
01
2.00E- 2.19E- Rac2, Socs3, Pias2, Socs2, Rac1, Pik3r5, Stat3, Jak2, Shc1, Rras2, Cdkn1a, Cish, Stat2,
04
01
Stat1
2.09E- 2.5E- C1R, Cfd, Serping1, C3, C1S, Cfb, C4a, Masp1, C2
04
01
2.14E- 1.25E- Rac2, Icam1, Nfkbie, Pik3R5, Pbx1, Ccl5, Jak2, Il6, Fcgr1a, Nr3c1, Il1R2, Shc1, Cxcl3,
04
01
Hspa4, Nfkbia, Ar, Ccl13, Cdkn1c, Serpine1, Stat1, Fkbp5, Nfkbib, Sra1, Vcam1,
Ccnh, Sele, Rac1, Stat3, Cebpb, Bcl2l1, Rras2, Il1rn, Cdkn1a, Fkbp4, Nr3c2

may promote dysfunction given its inflammatory [83],
pro-death [82, 84] and mitochondrial actions [84].
Current data suggest the A2AR may beneficially limit
LPS-dependent IκBζ induction to suppress injurious
lipocalin-2. Highly repressed adiponectin exerts anti-inflammatory, anti-oxidant and cardioprotective effects

[85, 86], thus downregulation is also likely to promote
inflammation and sensitize myocardium to oxidativestress and cell death. Curiously, Adipoq repression was
reduced with A2AR KO, suggesting a positive influence
of A 2A R activity on this response. These and other
changes relevant to pathogenesis of cardiac depression
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Fig. 6 Schematic of TLR, IL-1,
IL-6 and interferon receptor
activation of NFκB and JAKSTAT signalling and
transcriptional control. The
effects of A2AR KO- on LPSdependent gene changes are
highlighted. These pathways are
critical to cellular responses to
LPS and orchestration of
inflammation. Specific effects of
A2AR activity (based on effects of
receptor KO) on transcriptional
responses to LPS are highlighted
(red—increased expression;
blue—reduced expression)

are discussed further in the online Supplementary
material.
A2AR modulation of the endotoxemic transcriptome
Despite well-established anti-inflammatory effects of
acute A2AR agonism, the myocardial transcriptomic response to endotoxemia was largely insensitive to A2AR
KO (Figs. 3 and 4; Tables 7 and S9). Rather than a
broadly suppressive impact of A 2A R activity, only
10 % of the transcriptomic response was modified by
KO. This selective outcome is consistent with data for
cytokine/chemokine transcription and release—the majority of these responses were also unaltered by A2AR
deletion, which specifically modified Il6, Cxcl2, Cxcl5
and Csf3 induction (Fig. 4) and circulating IL-5, haptoglobin and CRP levels (Figs. 1 and 2). These responses
are nonetheless relevant to myocardial outcome: IL-6
initiates and expands inflammatory signalling, and
CXCL2 and CXCL5 both participate in cardiac inflammation and remodelling. Important IL-6 target genes
were highly induced with LPS, including Bcl2l1,
Cebpb, Irf1, JunB, Lbp, Socs3 and Timp1. By suppressing IL-6 transcription, potentially through IκBζ induction and STAT1 repression, A2AR activity may limit

Fig. 5

Impact of 24 h LPS challenge on cardiac transcription of the TLR
(upper panel) and interferon signalling paths (lower panel) in wild-type
mice (n = 6–8/group). Induced transcripts highlighted in red and
repressed in green. Shaded transcripts are altered by LPS by less than
the threshold value

cardiac IL-6 signalling. Functional annotation of A2AR
sensitive transcripts does support modulation of acute
phase response, JAK-STAT, MAPK, PRR and NFκB
pathways (Tables 7, S6 and S10). Figure 6 summarizes
these key changes, highlighting impacts of A2AR KO.
Through modifying a small number of key transcript
responses (Nfkbie, Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and
Rras2), A2AR activity may limit expansion of injurious
inflammation in endotoxemic myocardium. In contrast,
the cardio-depressant molecular profile appears insensitive to A2AR KO.
NFκB signalling The A2AR represses NFκB signalling via
multiple mechanisms in non-cardiac cells, including phosphorylation-/SUMOylation-dependent IκB degradation and
modulation of the SCF-E3 ubiquitin ligase complex [58].
The absence of A 2A Rs did modify the NFκB path in
endotoxemic myocardium (Fig. 6), amplifying proinflammatory Nfkbiz (IκBζ) induction while countering inhibitory Nfkbie (IκBε) induction. Enhanced transcription of IκBζ
and its targets Lcn2 and Il6 with A2AR KO suggests the receptor may suppress inflammation by inhibiting IκBζ induction and its transcriptional actions, while promoting IκBε induction to limit nuclear translocation of NFκB (Fig. 6).
In contrast, A2AR KO also reduced induction of molecules promoting NFκB signalling (Fig. 6): Eif2ak2/Pkr
inhibits IκBα expression and enhances NFκB signaling
and IFN-β expression; Btrc promotes degradation of
IκBα and Rac2 promotes cytokine-triggered NFκB
signalling and IFN-γ expression. It is unclear what the
balance of these changes might be, though repression
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Top canonical responses to LPS modified by A2AAR KO (the 15 most promoted or inhibited by A2AAR KO are shown)

Canonical Pathways

P value Ratio

Genes

LPS responses enhanced by A2AR KO (countered by A2AR activity)
7.41E- 5.06E- Hpx, Hp, Rras2, Pik3r1, Cp, Il6, Serpine1, Nr3c1, Orm1
04
02
Glucocorticoid receptor signalling
9.33E- 3.90E- Hspa4, Cxcl3, Rras2, Pik3r1, Cdkn1a, Tgfb2, Il6, Stat1, Serpine1, Hspa2,
04
02
Nr3c1
Glioma invasiveness signalling
1.29E- 8.47E- Timp4, Rras2, Pik3r1, Rhoj, Itgb3
03
02
Germ cell-sertoli cell junction signalling
1.45E- 5.00E- Rras2, Tuba8, Pak6, Map3k6, Pak3, Pik3r1, Tgfb2, Rhoj
03
02
Angiopoietin signalling
3.16E- 6.58E- Grb14, Rras2, Pak6, Pak3, Pik3r1
03
02
ILK signalling
3.55E- 4.26E- Ppp2r3a, Pik3r1, Vegfc, Atf4, Rhoj, Itgb6, Pgf, Itgb3
03
02
Ephrin receptor signalling
3.98E- 4.04E- Rras2, Pak6, Pak3, Vegfc, Atf4, Epha4, Efnb3, Pgf
03
02
ERK/MAPK signalling
4.37E- 4.10E- Rras2, Pak6, Pak3, Ppp2r3a, Ppp1R3c, Pik3r1, Atf4, Stat1
03
02
Pancreatic adenocarcinoma signalling
4.47E- 5.08E- Pik3r1, Cdkn1a, Tgfb2, Vegfc, Stat1, Pgf
03
02
HER-2 signalling in breast cancer
5.13E- 6.17E- Rras2, Pik3r1, Cdkn1a, Itgb6, Itgb3
03
02
Macrophage NO & ROS production
7.08E- 3.74E- Map3k6, Ppp2r3a, Ppp1r3c, Pik3r1, Rhoj, Irf8, Stat1
03
02
Hepatic fibrosis/stellate cell activation
1.05E- 4.48E- Cxcl3, Tgfb2, Vegfc, Il6, Stat1, Pgf
02
02
Circadian rhythm signalling
1.12E- 8.57E- Per3, Arntl, Atf4
02
02
HIF1α signalling
1.38E- 4.55E- Rras2, Pik3r1, Vegfc, Slc2a4, Pgf
02
02
JAK/Stat signalling
1.41E- 6.06E- Rras2, Pik3r1, Cdkn1a, Stat1
02
02
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
PXR/RXR activation
6.46E- 4.4E-02 Rac2, Prkar2b, Cyp2b6
04
Nicotinate and nicotinamide metabolism
3.98E- 2.94E- Cilp, Art5, Eif2ak2, Bst1
03
02
Amyloid processing
4.57E- 5.08E- Rac2, Prkar2b, Capn10
03
02
Glutamate receptor signalling
5.89E- 4.29E- Glul, Slc38a1, Homer1
03
02
AMPK signalling
9.55E- 2.40E- Rac2, Prkar2b, Adipoq, Eif4ebp1
03
02
PRRs in recognition of bacteria & viruses
9.77E- 3.66E- C3, Ddx58, Eif2ak2
03
02
NF-κB signalling
1.15E- 2.58E- Rac2, Nfkbie, Btrc, Eif2ak2
02
02
NF-κB activation by viruses
1.23E- 3.61E- Rac2, Nfkbie, Eif2ak2
02
02
Inhibition of angiogenesis by TSP1
1.55E- 5.56E- Rac2, Sdc1
02
02
Role of RIG1-like receptors in antiviral innate immunity
1.66E- 3.92E- Nfkbie, Ddx58
02
02
FXR/RXR activation
1.78E- 2.91E- Rac2, Sdc1
02
02
TR/RXR activation
1.78E- 3.03E- Rac2, Ucp1
02
02
PPARα/RXRα activation
1.86E- 2.22E- Prkar2b, Nfkbie, Adipoq
02
02
RANK signalling in osteoclasts
1.95E- 3.06E- Rac2, Nfkbie, Map3k2
02
02
Fcγ receptor-mediated phagocytosis in macrophages and
2.04E- 2.97E- Hmox1, Rac2, Hck
monocytes
02
02

Acute phase response signalling

Canonical pathways modified by LPS, ranked according to P-values determined by Fisher’s Exact Test. Also shown is the ratio reflecting the number of
molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in the path
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Table 7 Functional groupings of
genes for which LPS responses
were modified by ≥1.5-fold
(induction or repression) by A2AR
KO
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Functional grouping

P value

Number of genes

LPS responses enhanced by A2AR KO (countered by A2AR activity)
Molecular and cellular functions
Cellular Movement

1.10E-08–5.10E-03

58

Cell-To-Cell Signalling and Interaction
Cell Death

1.78E-06–5.40E-03
1.13E-05–4.87E-03

46
74

Cellular Growth and Proliferation

1.30E-05–5.40E-03

58

Cell Cycle

2.22E-05–4.86E-03

30

Physiological system development and function
Haematological System Development and Function

3.17E-07–5.40E-03

53

Haematopoiesis
Tissue Morphology

3.17E-07–4.79E-03
3.17E-07–4.79E-03

36
38

Immune Cell Trafficking

3.90E-07–5.10E-03

37

1.54E-06–4.25E-03

24

3.71E-08–5.03E-03
9.17E-08–3.81E-03
7.90E-07–3.81E-03

82
72
77

Cardiovascular System Development and Function
Disease and disorders
Cancer
Immunological Disease
Skeletal and Muscular Disorders
Inflammatory Response
Haematological Disease

1.78E-06–5.05E-03
2.44E-06–3.68E-03
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
Molecular and cellular functions
Carbohydrate Metabolism
2.24E-05–2.33E-02
Molecular Transport

46
37

6

2.38E-05–2.61E-02

24

Small Molecule Biochemistry
Lipid Metabolism
Cellular Compromise
Physiological system development and function
Cardiovascular System Development and Function

2.38E-05–2.87E-02
4.28E-05–2.87E-02
6.16E-05–2.61E-02

34
14
11

4.28E-05–2.97E-02

5

Organ Development
Organismal Functions
Haematological System Development and Function

4.28E-05–2.33E-02
9.49E-05–2.61E-02
2.54E-04–3.11E-02

7
4
13

2.54E-04–2.61E-02

6

6.16E-05–3.11E-02
8.22E-05–6.58E-03
1.34E-04–3.00E-02
2.54E-04–2.61E-02
2.54E-04–2.61E-02

15
10
30
14
30

Lymphoid Tissue Structure and Development
Disease and disorders
Inflammatory Response
Nutritional Disease
Genetic Disorder
Developmental Disorder
Neurological Disease

Functional groupings of LPS-responsive cardiac transcripts modified by A2AR KO (enhanced or repressed) by a
factor of ≥1.5-fold. Functional groups derived from IPA analysis are categorized into molecular and cellular
functions, physiological system development and function, and disease and disorders, and ranked according to
P value ranges determined by a Fisher’s Exact Test. Total numbers of involved genes are also shown

of the distal transcriptional effector IκBζ is predicted to
limit effects of up-stream changes. Failure of A2AR KO to
modify changes in genes recently implicated in
cardioprotective effects of NFκB signalling [47] (including induction of Ptx3, Plscr1, Sfi1 and Igfbp3 and repression of Car3, Dkk3, ai605517 and Grhl2) suggests

receptor activity might selectively modify injurious rather
than protective aspects of NFκB signalling.
JAK-STAT signalling In non-cardiac cells, A2AR agonism
also inhibits JAK-STAT signalling, via control of SOCS transcription [58] and ubiquitination/degradation of JAK-
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response yet not associated TLR and interferon
signalling.

Fig. 7 Comparison of expression values for select transcripts assessed
via array analysis and quantitative real-time PCR. Expression ratios are
relative to values in wild-type (WT) hearts treated with normal saline
(NS) and are thus shown for WTs treated with LPS for 24 h (WT LPS)
and A2AR KO hearts untreated (KO NS) or treated with LPS (KO LPS).
Data are means ± S.E.M, n = 6–8/group

phosphorylated STATs [87]. Despite no evidence for A2AR
modulation of Socs3 (induced with LPS unaltered by KO),
A2AR deletion did modify the JAK-STAT response, exaggerating induction of both Stat1 and the key activator Il6. Since
STAT1 is crucial to LPS-induced apoptosis in non-cardiac
cells [88], and mediates injury with ischemic insult [39],
A2AR-dependent suppression is predicted to be protective.
Deletion of A2ARs also enhanced endotoxemic induction of
Cdkn1a/p21Cip1/Waf1 (modulator of STAT1-dependent apoptosis and IFN-γ/STAT signalling, linked to poor sepsis outcomes [49]) and the signal transducer Rras2. These data collectively support beneficial A2AR modulation of JAK-STAT
activation in endotoxemic myocardium (Fig. 6).

Select impacts on acute phase response vs. TLR and interferon signalling The acute phase response is triggered by
IL-1, IL-6 and TNF-α and transduced via NFκΒ and
JAK-STAT signals. Additional to effects of KO on Il6
and JAK-STAT and NFκB paths, A2AR activity appears
to counter induction of key gene targets (Serpine1, Il6,
Cp, Hpx, Hp and Orm1). Conversely, A2AR activity was
also associated with greater induction of target genes C3
and Hmox and reduced induction of the glucocorticoid
receptor inhibiting this inflammatory response. While
mixed, collective shifts in JAK-STAT/NFκB paths support transcriptional suppression of the acute phase response via A 2 A R activity. However, while TLR/
interferon paths were among the most highly responsive
to LPS, A2AR KO did not substantially modify these
responses (augmenting induction of MyD88-responsive
Irf8 and altering downstream NFκB signalling). Major
changes in interferon signalling were also largely unmodified by A2AR KO (Fig. 6), suggesting select impacts of A2AR activity on elements of the acute phase

Novel effects of A2AR KO The impact of A2AR activity is
limited primarily to canonical elements of endotoxemia
(Tables 6, S10 and S11); however, several of the more
A2AR-sensitive transcriptional responses to LPS hint at novel
effects of A2AR signalling, including modulation of insulinsensitivity, hypertrophic growth/remodelling and cardiac
rhythmicity, together with influencing angiogenesis and vascular control.
Disruption of insulin-dependent glucose metabolism is an
important consequence of endotoxemia, and three of the most
A2AR-sensitive transcripts (Ptprf, Glut4/Slc2a4 and Glut12/
Slc2a12) govern insulin-dependent glucose uptake
(Table S9). Endotoxemic suppression of Glut4 and the secondary insulin-sensitive transporter Glut12 and the induction
of Ptprf (encoding protein tyrosine phosphatase, receptor type
F; implicated in insulin-resistance) were exaggerated >twofold with A2AR KO (Table S9). Endotoxemic suppression of
Glut4 and glucose uptake is reported in skeletal and cardiac
muscle [89]. Conversely, increased expression of Glut4 improves glucose uptake and limits myocardial dysfunction in
endotoxemia [89]. These responses to A2AR KO suggest regulatory influences of A2AR activity on glucose handling in
endotoxemic tissue.
Other highly A2AR-sensitive transcriptional responses
suggest A2AR modulation of myocardial remodelling, including shifts in Asb14 and Asb15, Ca3 and Ca4 and
Dnmt3a and Srpk2. Endotoxemic repression of transcripts
for 2 ankyrin repeat and SOCS box (ASB) proteins,
Asb14 and Asb15, was substantially exaggerated with
A2AR KO. The ASB family bind and target proteins for
degradation and regulate skeletal muscle development,
while roles in heart are unclear. The ASB15 protein enhances skeletal muscle protein synthesis [90] and delays
differentiation, potentially via modulating MAPK and
PI3K/Akt signalling [91]. This control may be important
in adaptive response to muscle load/activity. Carbonic
anhydrases are also implicated in myocardial hypertrophy,
with endotoxemic Car4 induction (the dominant cardiac
isoform) exaggerated and Car3 downregulation was
inhibited in A2AR KO hearts. The myocardial roles of
these enzymes are only beginning to be unravelled,
though they may promote hypertrophic responses by facilitating Na+-H+ and Cl-HCO3 exchanger over-activities,
while evidence from other cells suggests CAR3 may modify oxidative stress and apoptosis. Similarly, Srpk2 induction was augmented in the absence of A2ARs, encoding a
serine/arginine (SR) protein kinase (SRPK) that phosphorylates SR domain-containing proteins within
interchromatin granule clusters/nuclear speckles to regulate pre-mRNA splicing. The SRPK2 protein also plays an
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important role in cell proliferation and apoptosis.
Additionally, downregulation of the methyltransferase
transcript Dnmt3a, governing growth and function of embryonic myocytes [92], appears to be countered by A2AR
activity, which may also limit cardiac fibrosis/remodelling
[93]. Collectively, this suite of A2AR responsive changes
may limit myocardial hypertrophy and remodelling responses to inflammatory insult. This is consistent with
functional groupings sensitive to A2AR KO, including determinants of cell cycle, growth, proliferation and death
and cardiovascular development (Table 7) and shifts in
canonical hypertrophy pathways (Tables S10 and S11).
Curiously, A2AR activity also limited LPS induction of
Hcn1 (Table S9). The HCN proteins mediate the pacemaker
(funny) current governing cardiac automaticity/excitability.
While HCN4 is the most highly expressed, HCN1 is significantly expressed within the conduction network, contributes
to cardiac rhythmicity [94] and is up-regulated in hypertrophy
and heart failure. Endotoxemic induction may thus promote
arrhythmicity, while A2AR activity appears to suppress this
change.
Finally, A2AR KO modified a broader range of vascular control and growth pathways in endotoxemic (vs.
healthy) hearts. Vascular dysfunction is a critical to organ damage and mortality and may involve NOS overactivity in some vascular beds. Deletion of the A2AR
modified NO signalling together with renin-angiotensin
signalling (Table S10), while cardiac arteriopathy was
identified as a pathological process sensitive to KO
(Table S11). These responses support influences of
A2AR signalling on vascular pathology. We have previously shown endotoxemia impairs coronary hyperaemia,
a dysfunction mimicked by KO of (and potentially involving) the A2AR [23]. Additionally, there is an apparent coronary ‘over-supply’ relative to myocardial demand in endotoxemic hearts (Table 1), owing to 25–
30 % lower contractile function without reductions in
coronary perfusion. The absence of coronary coupling
to ventricular activity, described by us in this and other
models [95, 96], suggests additional coronary dysregulation (though this effect is neither replicated nor modified by A2AR KO). Multiple paths/mediators regulating
angiogenesis were also sensitive to A 2A R KO in
endotoxemic heart, including shifts in VEGF, HIF-1α,
angiopoietin, TGF-β, GM-CSF, PDGF and IGF-1 pathways (Table S10) and key regulatory molecules (including exaggerated induction of Il6, Pgf, Tgfb2, Tgfb2r,
Angptl4 and Amotl1; exaggerated suppression of Vegfc
and reduced suppression of Qk) (Table S9). While the
A2B receptor is more broadly implicated in control of
angiogenesis, these changes suggest A2A R-dependent
processes may influence angiogenesis in the context of
uncontrolled inflammation.
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RT-qPCR confirmation of microarray-detected responses
Data confirm agreement between transcript expression determined via RT-qPCR and microarray methods (Fig. 7),
with PCR further highlighting distinct transcriptional effects of A2A R KO: in some cases, KO eliminates responses to LPS (Acta1); alters baseline yet not LPSdependent expression (Amid or Dbp); enhances induction
(Txnip) or repression (Cidec) in response to vehicle and
LPS or reduces gene expression in the vehicle group
while negating further changes with LPS (Eif4ebp2 and
Slc38a1). Confirming the microarray approach, some of
these responses are also functionally relevant. For example, Txnip encodes a stress-responsive protein inhibiting
the anti-oxidant/signalling molecule thioredoxin.
Reductions in TXNIP inhibit vascular inflammation and
TNF-α signalling [97], TXNIP dysregulation promotes inflammatory disease [98] and elevations in TXNIP facilitate apoptosis [99]. Inhibition of Txnip induction by A2AR
activity may thus enhance protective thioredoxin
functionality.
Study limitations
Several study limitations are worth noting. While essential
genesis of cardiac injury is studied and understood within
the in situ organ, this entails experimental limitations inherent to in vivo studies of organ dysfunction in sepsis/
endotoxemia [15, 16, 20, 21, 24, 41, 42, 49]. Organ injury
in these settings not only involves intrinsic organ-specific
mechanisms but also influenced by extrinsic factors, including shifts in systemic inflammation, haemodynamics
and neuroendocrine influences (with relative impacts of
these factors difficult to delineate). Although we assess
the intrinsic myocardial dysfunction in ex vivo tissue (together with in vivo markers of cardiac damage), we cannot isolate potential influences of A2AR KO on cardiac
loading, neurohumoral factors or indeed systemic inflammation. That said, while A2AR KO augmented some inflammatory markers, systemic and cardiac cytokine responses were largely insensitive to KO and the myocardial response was very selectively modified, indicating distinct effects of A2AR activity on cardiac injury processes.
We are also unable to detail cell-specific origins of myocardial transcriptional changes. Migrating inflammatory
cells could influence the transcriptomic profile for intact
myocardium, though, as detailed in the Supplementary
material, the expression profile of endotoxemic myocardial tissue is inconsistent with major contamination from
such cells. An added limitation relates to the intriguing
observation of both age- and sex-dependent mortality effects of LPS and A2ARs (Fig. S3). This unfortunately
precluded any detailed interrogation of these outcomes
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due to poor survival in older KO mice. Future work might
focus specifically on responses to LPS/sepsis in clinically
relevant aged cohorts, correlating age-dependent
transcriptomic and phenotypic outcomes. Finally, while
profound transcriptional changes observed in the current
profiling study are predicted to translate to functionally
relevant protein changes, this exploratory analysis does
not directly confirm altered protein expression.

Conclusions
Deletion of the A2AR induces modest effects in healthy myocardium, shifting transcription of G protein coupled cAMP/PKA,
MEKK2 and cGMP/NO signalling downstream of this and other GPCRs, without impacting cardiac function. However, the
receptor may play a retaliatory role in selectively suppressing
inflammatory signalling and injury, yet, not contractile depression, in endotoxemic myocardium. Cardiac endotoxemia itself is
characterized by profound upregulation of acute-phase response,
PRR/TLR and interferon signalling and cell death and remodelling pathways, together with broad suppression of primary determinants of contractility (Ca2+, ß-adrenergic and PKA signalling; mitochondrial function; electromechanical coupling) and
induction of cardio-depressant genes (Lcn2, S100a8/S100a9,
Icam1, Vcam1, Nox2, Cox2, Tnfr1 and Fas). This complex transcriptome is selectively A2AR sensitive, with effects of KO implicating modulation of key regulatory molecules (Nfkbie,
Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and Rras2) to suppress myocardial JAK-STAT/NFκB and pro-inflammatory IL-6 and TLR
signalling, together with influencing determinants of insulin-sensitivity, hypertrophy/remodelling and vascular function/angiogenesis. In contrast, endotoxemic suppression of β-adrenergic,
PKA, Ca2+ signalling, electromechanical and mitochondrial
function pathways appears insensitive to A2AR KO, as does
contractile dysfunction itself.
Acknowledgments This work was supported by the National Heart,
Lung and Blood Institute grants HL-74001 (RRM), HL-027339 (SJM)
and HL-48839 (PAH), an American Heart Association Southeast Affiliate
Grant-in-Aid (PAH), a grant from the National Health and Medical
Research Council of Australia (JPH) and the American Lebanese
Syrian Associated Charities (RRM). We gratefully acknowledge the technical assistance of Kiel J. Headrick and Mary A. Cerniway.
Authors’ contributions Conceived and designed the experiments:
MER, KJA, JPH, RRM, SJM. Performed the experiments: MER, KJA,
RRM, BT. Analysed data: KJA, MER, JPH, RRM, BT, LD. Generated
and characterized KO mice: CL, PAH. Contributed reagents/materials/
analytical tools: RRM, CL, PAH, KJA, JPH. Wrote the paper: KJA,
MER, JPH, RRM, LMD, SJM.

Purinergic Signalling (2017) 13:27–49

References
1.
2.

3.

4.

5.

6.

7.
8.

9.

10.

11.

12.

13.

14.

15.

16.

Compliance with ethical standards
17.
Conflict of interest The authors declare that they have no conflict of
interest.

Merx MW, Weber C (2007) Sepsis and the heart. Circulation 116:
793–802
Balija TM, Lowry SF (2011) Lipopolysaccharide and sepsisassociated myocardial dysfunction. Curr Opin Infect Dis 24:248–
253
Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.
Nat Rev Drug Discov 7:759–770
Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M,
Caldwell C et al (2004) Physiological control of immune response
and inflammatory tissue damage by hypoxia-inducible factors and
adenosine A2A receptors. Annu Rev Immunol 22:657–682
Sitkovsky MV, Ohta A (2005) The ‘danger’ sensors that STOP the
immune response: the A2 adenosine receptors? Trends Immunol 26:
299–304
Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M (2004)
Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor
in vivo. J Immunol 173:21–24
Ohta A, Sitkovsky M (2009) The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol 9:501–506
Headrick JP, Peart JN, Reichelt ME, Haseler LJ (2011) Adenosine
and its receptors in the heart: regulation, retaliation and adaptation.
Biochim Biophys Acta 1808:1413–1428
Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA
et al (2006) Myocardial infarct-sparing effect of adenosine A2A
receptor activation is due to its action on CD4+ T lymphocytes.
Circulation 114:2056–2064
Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR,
Linden J (2008) Adenosine A2A receptor activation reduces infarct
size in the isolated, perfused mouse heart by inhibiting resident
cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol
295:H1825–H1833
Glover DK, Riou LM, Ruiz M, Sullivan GW, Linden J, Rieger JM
et al (2005) Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor
agonist, in reperfused canine myocardium. Am J Physiol Heart
Circ Physiol 288:H1851–H1858
Boucher M, Pesant S, Falcao S, de Montigny C, Schampaert E,
Cardinal R, Rousseau G (2004) Post-ischemic cardioprotection by
A2A adenosine receptors: dependent of phosphatidylinositol 3kinase pathway. Cardiovasc Pharmacol 43:416–422
Ribé D, Sawbridge D, Thakur S, Hussey M, Ledent C, Kitchen I
et al (2008) Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity. Free Radic Biol Med 44:1433–
1442
Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H et al
(2009) Adenosine A2A and A2B receptors work in concert to induce
a strong protection against reperfusion injury in rat hearts. J Mol
Cell Cardiol 47:684–690
He X, JL H, Li J, Zhao L, Zhang Y, Zeng YJ et al (2013) A feedback
loop in PPARγ-adenosine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mouse model of LPSinduced acute lung injury. Cell Signal 25:1913–1923
Gonzales JN, Gorshkov B, Varn MN, Zemskova MA, Zemskov
EA, Sridhar S et al (2014) Protective effect of adenosine receptors
against lipopolysaccharide-induced acute lung injury. Am J Physiol
Lung Cell Mol Physiol 306:L497–L507
Odashima M, Otaka M, Jin M, Komatsu K, Wada I, Matsuhashi T
et al (2005) Selective A2A adenosine agonist ATL-146e attenuates
acute lethal liver injury in mice. J Gastroenterol 40:526–529

Purinergic Signalling (2017) 13:27–49
18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

Rebola N, Simões AP, Canas PM, Tomé AR, Andrade GM, Barry
CE et al (2011) Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J
Neurochem 117:100–111
Thiel M, Kreimeier U, Holzer K, Moritz S, Peter K, Messmer K
(1998) Effects of adenosine on cardiopulmonary functions and
oxygen-derived variables during endotoxemia. Crit Care Med
26:322–337
Tofovic SP, Zacharia L, Carcillo JA, Jackson EK (2001) Inhibition
of adenosine deaminase attenuates endotoxin-induced release of
cytokines in vivo in rats. Shock 16:196–202
Braun-Dullaeus RC, Dietrich S, Schoaff MJ, Sedding DG,
Leithaeuser B, Walker G et al (2003) Protective effect of 3deazaadenosine in a rat model of lipopolysaccharide-induced myocardial dysfunction. Shock 19:245–251
Reutershan J, Cagnina RE, Chang D, Linden J, Ley K (2007)
Therapeutic anti-inflammatory effects of myeloid cell adenosine
receptor A2a stimulation in lipopolysaccharide-induced lung injury.
J Immunol 179:1254–1263
Reichelt ME, Ashton KJ, Tan XL, Mustafa SJ, Ledent C,
Delbridge LM et al (2013) The adenosine A2A receptor—
myocardial protectant and coronary target in endotoxemia.
Int J Cardiol 166:672–680
Li J, Zhao L, He X, Zeng YJ, Dai SS (2013) Sinomenine protects
against lipopolysaccharide-induced acute lung injury in mice via
adenosine A2A receptor signaling. PLoS One 8:e59257
Németh ZH, Csóka B, Wilmanski J, Xu D, Lu Q, Ledent C et al
(2006) Adenosine A2A receptor inactivation increases survival in
polymicrobial sepsis. J Immunol 176:5616–5626
Belikoff B, Hatfield S, Sitkovsky M, Remick DG (2011)
Adenosine negative feedback on A2A adenosine receptors
mediates hyporesponsiveness in chronically septic mice. Shock
35:382–387
Ouyang X, Ghani A, Malik A, Wilder T, Colegio OR, Flavell RA
et al (2013) Adenosine is required for sustained inflammasome
activation via the A2A receptor and the HIF-1α pathway. Nat
Commun 4:2909
Nassi A, Malorgio F, Tedesco S, Cignarella A, Gaion RM (2016)
Upregulation of inducible NO synthase by exogenous adenosine in
vascular smooth muscle cells activated by inflammatory stimuli in
experimental diabetes. Cardiovasc Diabetol 15:32
Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG
et al (2006) Role of A2B adenosine receptor signaling in adenosinedependent pulmonary inflammation and injury. J Clin Invest 116:
2173–2182
Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee
H et al (2006) Adenosine a(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 148:1144–1155
Stoll M, Kim YO, Bebich B, Robson SC, Schuppan D (2012) The
selective adenosine 2B receptor antagonist MRS1754 mitigates
hepatic collagen deposition during fibrosis progression and induces mild fibrosis regression. Gastroenterology 142(Suppl 1):
S974–S975
Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O,
Okada K et al (2006) Long-term stimulation of adenosine A2b
receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 114:1923–1932
Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Yet al
(2003) Activation of adenosine A1 receptor attenuates cardiac
hypertrophy and prevents heart failure in murine left ventricular
pressure-overload model. Circ Res 93:759–766
Jacobs AT, Ignarro LJ (2001) Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide
synthase induction in RAW 264.7 macrophages. J Biol
Chem 276:47950–47957

47
35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

Park EJ, Park SY, Joe EH, Jou I (2003) 15d-PGJ2 and rosiglitazone
suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in
glia. J Biol Chem 278:14747–14752
Kim OS, Park EJ, Joe EH, Jou I (2002) JAK-STAT signaling mediates gangliosides-induced inflammatory responses in brain
microglial cells. J Biol Chem 277:40594–40601
Niu J, Wang K, Graham S, Azfer A, Kolattukudy PE (2011) MCP1-induced protein attenuates endotoxin-induced myocardial dysfunction by suppressing cardiac NF-кB activation via inhibition of
IкB kinase activation. J Mol Cell Cardiol 51:177–186
Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiemermann C
(2013) Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech 6:1031–
1042
Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK
et al (2001) JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 104:325–
329
McCormick J, Suleman N, Scarabelli TM, Knight RA, Latchman
DS, Stephanou A (2012) STAT1 deficiency in the heart protects
against myocardial infarction by enhancing autophagy. J Cell Mol
Med 16:386–393
Wong ML, O’Kirwan F, Khan N, Hannestad J, KH W, Elashoff D
et al (2003) Identification, characterization, and gene expression
profiling of endotoxin-induced myocarditis. Proc Natl Acad Sci U
S A 100:14241–14246
Mastronardi CA, Licinio J, Wong ML (2010) Candidate biomarkers
for systemic inflammatory response syndrome and inflammation: a
pathway for novel translational therapeutics.
Neuroimmunomodulation 17:359–368
Cuenca J, Goren N, Prieto P, Martín-Sanz P, Boscá L (2007) Selective
impairment of nuclear factor-kappaB-dependent gene transcription in
adult cardiomyocytes: relevance for the regulation of the inflammatory
response in the heart. Am J Pathol 171:820–828
Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S et al
(2012) The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells.
PLoS One 7:e39317
Yang J, Zheng X, Haugen F, Darè E, Lövdahl C, Schulte G et al
(2014) Adenosine increases LPS-induced nuclear factor kappa B
activation in smooth muscle cells via an intracellular mechanism
and modulates it via actions on adenosine receptors. Acta Physiol
(Oxf) 210:590–599
Boengler K, Hilfiker-Kleiner D, Drexler H et al (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol
Ther 120:172–185
Wilhide ME, Tranter M, Ren X, Chen J, Sartor MA, Medvedovic M
et al (2011) Identification of a NF-κB cardioprotective gene program: NF-κB regulation of Hsp70.1 contributes to cardioprotection
after permanent coronary occlusion. J Mol Cell Cardiol 51:82–89
Bergmann MW, Loser P, Dietz R, von Harsdorf R (2001) Effect of
NF-kappa B inhibition on TNF-alpha-induced apoptosis and downstream pathways in cardiomyocytes. J Mol Cell Cardiol 33:1223–
1232
Rudiger A, Dyson A, Felsmann K, Carré JE, Taylor V, Hughes S
et al (2013) Early functional and transcriptomic changes in the
myocardium predict outcome in a long-term rat model of sepsis.
Clin Sci (Lond) 124:391–401
Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi
M, Vanderhaeghen JJ et al (1997) Aggressiveness, hypoalgesia and
high blood pressure in mice lacking the adenosine A2a receptor.
Nature 388:674–678
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis
KJ, Scherf U et al (2003) Exploration, normalization, and

48

52.

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

67.

68.

Purinergic Signalling (2017) 13:27–49
summaries of high density oligonucleotide array probe level
data. Biostatistics 4:249–264
Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al
(2003) TM4: a free, open-source system for microarray data management and analysis. BioTechniques 34:374–378
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of
microarrays applied to the ionizing radiation response. Proc Natl
Acad Sci U S A 98:5116–5121
Budiono BP, See Hoe LE, Peart JN, Sabapathy S, Ashton KJ et al
(2012) Voluntary running in mice beneficially modulates myocardial
ischemic tolerance, signaling kinases and gene expression patterns.
Am J Physiol Regul Integr Comp Physiol 302:R1091–R1100
Everaert BR, Boulet GA, Timmermans JP, Vrints CJ (2011)
Importance of suitable reference gene selection for quantitative
real-time PCR: special reference to mouse myocardial infarction
studies. PLoS One 6:e23793
Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K (1996)
Lipopolysaccharide-induced lethality and cytokine production in
aged mice. Infect Immun 64:769–774
Chen J, Chiazza F, Collino M, Patel NS, Coldewey SM,
Thiemermann C (2014) Gender dimorphism of the cardiac dysfunction in murine sepsis: signalling mechanisms and age-dependency. PLoS One 9:e100631
Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. Sci World J 11:320–
339
Ding L, Hanawa H, Ota Y, Hasegawa G, Hao K, Asami F et al
(2010) Lipocalin-2/neutrophil gelatinase-B associated lipocalin is
strongly induced in hearts of rats with autoimmune myocarditis and
in human myocarditis. Circ J 74:523–530
Blackburn MR, Vance CO, Morschl E, Wilson CN (2009)
Adenosine receptors and inflammation. Handb Exp Pharmacol
193:215–269
Nadeem A, Ponnoth DS, Ansari HR, Batchelor TP, Dey RD,
Ledent C, Mustafa SJ (2009) A2 A adenosine receptor deficiency
leads to impaired tracheal relaxation via NADPH oxidase pathway
in allergic mice. J Pharmacol Exp Ther 330:99–108
Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA
et al (2005) Genetic and pharmacological inactivation of adenosine
A2 A receptor reveals an Egr-2-mediated transcriptional regulatory
network in the mouse striatum. Physiol Genomics 23:89–102
Sweeney TE, Suliman HB, Hollingsworth JW, Welty-Wolf KE,
Piantadosi CA (2011) A toll-like receptor 2 pathway regulates the
Ppargc1a/b metabolic co-activators in mice with staphylococcal
aureus sepsis. PLoS One 6:e25249
Barber RC, Maass DL, White DJ, Chang LY, Horton JW (2008)
Molecular or pharmacologic inhibition of the CD14 signaling pathway protects against burn-related myocardial inflammation and
dysfunction. Shock 30:705–713
Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA et al (2004)
Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784–789
Avlas O, Fallach R, Shainberg A, Porat E, Hochhauser E (2011)
Toll-like receptor 4 stimulation initiates an inflammatory response
that decreases cardiomyocyte contractility. Antioxid Redox Signal
15:1895–1909
Ha T, Hua F, Li Y, Ma J, Gao X, Kelley J, Zhao A et al (2006)
Blockade of MyD88 attenuates cardiac hypertrophy and decreases
cardiac myocyte apoptosis in pressure overload-induced cardiac
hypertrophy in vivo. Am J Physiol Heart Circ Physiol 290:H985–
H994
Hua F, Ha T, Ma J, Gao X, Kelley J, Williams DL et al (2005)
Blocking the MyD88-dependent pathway protects the myocardium
from ischemia/reperfusion injury in rat hearts. Biochem Biophys
Res Commun 338:1118–1125

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC et al
(2008) Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am
J Physiol Heart Circ Physiol 295:H1311–H1318
Rubin LJ, Keller RS, Parker JL, Adams HR (1994) Contractile
dysfunction of ventricular myocytes isolated from endotoxemic
Guinea pigs. Shock 2:113–120
Abi-Gerges N, Tavernier B, Mebazaa A, Faivre V, Paqueron X,
Payen D et al (1999) Sequential changes in autonomic regulation
of cardiac myocytes after in vivo endotoxin injection in rat. Am J
Respir Crit Care Med 160:1196–1204
Bensard DD, Banerjee A, McIntyre RC Jr, Berens RL, Harken AH
(1994) Endotoxin disrupts beta-adrenergic signal transduction in
the heart. Arch Surg 129:198–204
Kadoi Y, Saito S, Fujita N, Morita T, Fujita T (1996) Alterations in
the myocardial β-adrenergic system during experimental
endotoxemia. J Anesth 10:49–54
Yasuda S, Lew WY (1997) Lipopolysaccharide depresses cardiac
contractility and beta-adrenergic contractile response by decreasing
myofilament response to Ca2+ in cardiac myocytes. Circ Res 81:
1011–1020
Vanasco V, Magnani ND, Cimolai MC, Valdez LB, Evelson P,
Boveris A, Alvarez S (2012) Endotoxemia impairs heart mitochondrial function by decreasing electron transfer, ATP synthesis and
ATP content without affecting membrane potential. J Bioenerg
Biomembr 44:243–252
McDonald TE, Grinman MN, Carthy CM, Walley KR (2000)
Endotoxin infusion in rats induces apoptotic and survival pathways
in hearts. Am J Physiol Heart Circ Physiol 279:H2053–H2061
Cai J, Lu S, Yao Z, Deng YP, Zhang LD, JW Y et al (2014)
Glibenclamide attenuates myocardial injury by lipopolysaccharides in
streptozotocin-induced diabetic mice. Cardiovasc Diabetol 13:106
Jianhui L, Rosenblatt-Velin N, Loukili N, Pacher P, Feihl F, Waeber
B, Liaudet L (2010) Endotoxin impairs cardiac hemodynamics by
affecting loading conditions but not by reducing cardiac inotropism.
Am J Physiol Heart Circ Physiol 299:H492–H501
Vanasco V, Cimolai MC, Evelson P, Alvarez S (2008) The oxidative stress and the mitochondrial dysfunction caused by
endotoxemia are prevented by alpha-lipoic acid. Free Radic Res
42:815–823
Boyd JH, Kan B, Roberts H, Wang Y, Walley KR (2008) S100 A8
and S100 A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res
102:1239–1246
Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE et al
(2009) Increased systemic and myocardial expression of neutrophil
gelatinase-associated lipocalin in clinical and experimental heart
failure. Eur Heart J 30:1229–1236
Xu G, Ahn J, Chang S, Eguchi M, Ogier A, Han S et al (2012)
Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem 287:4808–4817
Aigner F, Maier HT, Schwelberger HG, Wallnofer EA, Amberger
A, Obrist P et al (2007) Lipocalin-2 regulates the inflammatory
response during ischemia and reperfusion of the transplanted heart.
Am J Transplant 7:779–788
Yang B, Fan P, Xu A, Lam KS, Berger T, Mak TW, Tse HF et al
(2012) Improved functional recovery to I/R injury in hearts from
lipocalin-2 deficiency mice: restoration of mitochondrial function
and phospholipids remodeling. Am J Transl Res 4:60–71
Smith CC, Yellon DM (2011) Adipocytokines, cardiovascular
pathophysiology and myocardial protection. Pharmacol Ther
129:206–219
Nanayakkara G, Kariharan T, Wang L, Zhong J, Amin R (2012)
The cardioprotective signaling and mechanisms of adiponectin.
Am J Cardiovasc Dis 2:253–266

Purinergic Signalling (2017) 13:27–49
87.

Safhi MM, Rutherford C, Ledent C, Sands WA, Palmer TM (2010)
Priming of signal transducer and activator of transcription proteins
for cytokine-triggered polyubiquitylation and degradation by the
A2A adenosine receptor. Mol Pharmacol 77:968–978
88. Kristof AS, Marks-Konczalik J, Billings E, Moss J (2003)
Stimulation of signal transducer and activator of transcription-1
(STAT1)-dependent gene transcription by lipopolysaccharide and
interferon-gamma is regulated by mammalian target of rapamycin.
J Biol Chem 278:33637–33644
89. Otero YF, Mulligan KX, Barnes TM, Ford EA, Malabanan CM, Zong
H et al (2016) Enhanced glucose transport, but not phosphorylation
capacity, ameliorates lipopolysaccharide-induced impairments in
insulin-stimulated muscle glucose uptake. Shock 45:677–685
90. McDaneld TG, Hannon K, Moody DE (2006) Ankyrin repeat and
SOCS box protein 15 regulates protein synthesis in skeletal muscle.
Am J Physiol Regul Integr Comp Physiol 290:R1672–R1682
91. McDaneld TG, Spurlock DM (2008) Ankyrin repeat and suppressor
of cytokine signaling (SOCS) box-containing protein (ASB) 15 alters
differentiation of mouse C2C12 myoblasts and phosphorylation of
mitogen-activated protein kinase and Akt. J Anim Sci 86:2897–2902
92. Fang X, Poulsen RR, Wang-Hu J, Shi O, Calvo NS, Simmons CS,
et al. (2016) Knockdown of DNA methyltransferase 3a alters gene
expression and inhibits function of embryonic cardiomyocytes.
FASEB J. 2016 Jun 15.

49
93.

Tao H, Yang JJ, Chen ZW, SS X, Zhou X, Zhan HY et al (2014)
DNMT3A silencing RASSF1A promotes cardiac fibrosis through
upregulation of ERK1/2. Toxicology 323:42–50
94. Fenske S, Krause SC, Hassan SI, Becirovic E, Auer F, Bernard R
et al (2013) Sick sinus syndrome in HCN1-deficient mice.
Circulation 128:2585–2594
95. Flood AJ, Willems L, Headrick JP (2002) Coronary function and
adenosine receptor-mediated responses in ischemic-reperfused
mouse heart. Cardiovasc Res 55:161–170
96. Reichelt ME, Willems L, Hack BA, Peart JN, Headrick JP (2009)
Cardiac and coronary function in the Langendorff-perfused mouse
heart model. Exp Physiol 94:54–70
97. Yamawaki H, Pan S, Lee RT, Berk BC (2005) Fluid shear
stress inhibits vascular inflammation by decreasing
thioredoxin-interacting protein in endothelial cells. J Clin
Invest 115:733–738
98. Takahashi Y, Masuda H, Ishii Y, Nishida Y, Kobayashi M, Asai S
(2007) Decreased expression of thioredoxin interacting protein
mRNA in inflamed colonic mucosa in patients with ulcerative
colitis. Oncol Rep 18:531–535
99. Chen CL, Lin CF, Chang WT, Huang WC, Teng CF, Lin YS (2008)
Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated
pathway. Blood 111:43

